e roche finance report finance report finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales chf chf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december definition cer see core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business free cash flow concept fully described pages reconciliations ifrs cash flow free cash flow given therefinance brief roche roche group reported strong overall results sales grew constant exchange rates cer ifrs net income increased cer core earnings per share increased cer sales group sales increased cer chf billion growth chf terms pharmaceuticals sales growth cer due new medicines ocrevus hemlibra tecentriq perjeta oncology addition tecentriq continued growth franchise avastin biosimilars estimated negative impact chf billion sales immunology sales increased led actemraroactemra esbriet diagnostics sales showed growth cer immunodiagnostics business major contributor operating results core operating profit increased cer chf billion increase chf terms research development expenditure grew cer chf billion core basis focus oncology neuroscience immunology therapeutic areas research development costs represented group sales ifrs operating results include noncore expenses pretax chf billion major factors chf billion amortisation charges intangible assets chf billion impairment goodwill intangible assets notably chf billion relating diabetes care business nonoperating results financing costs ifrs increased chf billion due early debt redemption losses chf billion income tax expenses ifrs decreased cer chf billion effective core tax rate decreased mainly due impacts resolution several tax disputes net income ifrs net income increased cer chf billion chf terms due base effect high goodwill impairment core earnings per share increased cer chf chf terms cash flows operating free cash flow increased chf billion underlying cash generation led increase operating free cash flow cer chf terms free cash flow increased cer chf terms chf billion driven higher operating free cash flow financial position net working capital decreased cer driven pharmaceuticals division net debt decreased chf billion chf billion free cash flow covered dividends chf billion net cash payments spark therapeutics gross debt decreased cer chf billion credit ratings strong moodys aa standard poors aa shareholder return dividends proposal made increase dividends chf per share would represent rd consecutive year dividend growth would result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles noncurrent liabilities operating segment information current liabilities revenue provisions contingent liabilities net financial expense debt income taxes equity attributable roche shareholders mergers acquisitions subsidiaries global restructuring plans noncontrolling interests property plant equipment employee benefits goodwill pensions postemployment benefits intangible assets equity compensation plans inventories leases accounts receivable earnings per share nonvoting equity security marketable securities statement cash flows cash cash equivalents risk management noncurrent assets related parties current assets list subsidiaries associates accounts payable significant accounting policies report roche management internal control financial reporting statutory auditors report general meeting roche holding ltd basel independent reasonable assurance report internal control financial reporting multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings statutory auditors report general meeting roche holding ltd basel financial review roche group financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche group reported sales growth constant exchange rates cer led core operating profit growth increase core eps ifrs net income increased due business growth base impact high goodwill impairments sales growth continued driven pharmaceuticals divisions new medicines compensated biosimilar competition group improved operating profitability continuing investments research development supporting launch new products operating free cash flow chf billion increase driven higher cash generation pharmaceuticals business divisional operating results pharmaceuticals diagnostics corporate group chf chf chf chf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase roche finance report roche group financial review sales pharmaceuticals division chf billion chf billion increase cer new products major growth driver ocrevus hemlibra tecentriq perjeta together contributing additional chf billion cer new sales offset estimated chf billion cer impact biosimilars sales europe japan second half us broader market penetration led sales increase china chf billion ocrevus sales higher chf billion led us launch rollouts hemlibra continued sales reaching chf billion tecentriq sales grew regions largest contributions coming higher demand us europe well newly launched indications perjeta sales chf billion increase growth across regions avastin sales higher mainly due growth china us europe japan sales mabtherarituxan herceptin fell chf billion cer due biosimilar competition us first biosimilar versions mabtherarituxan herceptin avastin came market second half estimated chf billion cer impact sales diagnostics division reported sales chf billion increase cer major growth area centralised point care solutions represented divisions sales grew led growth immunodiagnostics business molecular diagnostics sales increased due increased demand blood screening diabetes care sales increased driven accuchek guide product line north america pharmaceuticals divisions core operating profit increased cer ahead sales growth royalty operating income decreased chf billion total fall chf billion following expiry cabilly patent end partially offset product disposal gains higher profitshare income cost sales increased sales growth manufacturing costs growing due favourable product mix lower inventory writeoffs royalty expenses growing marketing distribution costs grew due increased spending product launches rollouts including tecentriq ocrevus xofluza well rampup marketing activities new strategic businesses research development costs grew oncology neuroscience immunology representing significant areas spending diagnostics division core operating profit increased cer behind sales growth cost sales grew due higher costs external suppliers technical engineering services research development increased due spending new projects within centralised point care solutions portfolio laboratory automation ifrs operating profit increased pharmaceuticals division fell diagnostics division results divisions impacted impairments goodwill intangible assets current year comparative period results include chf billion impairments largest item goodwill impairment chf billion relating diabetes care business impairments goodwill intangible assets chf billion including chf billion relating intermune acquisition amortisation intangible assets chf billion chf billion expenses global restructuring plans operating free cash flow chf billion increase cer due higher cash generation pharmaceuticals business lower capital expenditure partly offset higher investments intangible assets net working capital decreased compared driven pharmaceuticals division higher rebate chargeback accruals lower net trade working capital free cash flow chf billion increase chf billion mainly due higher operating free cash flow financing costs cer higher ifrs basis chf billion mainly due losses early debt redemption chf billion net income equity securities showed gains chf billion roche venture fund investments income tax expenses lower groups effective core tax rate compared mainly due impacts resolution several tax disputes impact percentage points effective core tax rate implementation swiss tax reform noncore transitional impact groups deferred tax positions chf billion impact tax payments net income increased cer ifrs basis chf billion core basis chf billion driven cases operating results ifrs net income additionally affected base impact significant goodwill impairments results expressed swiss francs negatively impacted stronger swiss franc average euro latin american currencies partly offset appreciation us dollar swiss franc percentage point impact sales core operating profit expressed swiss francs compared constant exchange rates percentage point impact core eps roche finance report financial review roche group income statement change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf see pages definition core results core eps roche finance report roche group financial review leases effective january group implemented ifrs leases ifrs replaces existing leases guidance including ias leases group applied cumulative catchup method option transition meaning comparative results restated details given note annual financial statements main impact new standard bring operating leases onto balance sheet new standard results carrying value leased assets rightofuse assets increasing chf billion january lease liabilities increasing similar amount leases represent primarily office facilities motor vehicles application new standard results part previously reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group currently expect effect material amount chf million application new standard materially impact groups alternative performance measures classification changes within core eps operating free cash flow totals largely unaffected groups definition net debt include lease liabilities new standard impact ebitda details given pages mergers acquisitions december group acquired controlling interest spark therapeutics inc spark therapeutics publicly owned us company based philadelphia pennsylvania listed nasdaq stock market spark therapeutics fully integrated commercial company committed discovering developing delivering gene therapies spark therapeutics reported pharmaceuticals division cash purchase consideration usd billion equivalent chf billion chf million noncore income reversal contingent consideration provisions details given notes annual financial statements global restructuring plans group continued implementation various global restructuring plans initiated prior years global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs includes strategy plans diagnostics division includes pharmaceuticals divisions strategic realignment manufacturing network resourcing flexibility biologics manufacturing network includes plans outsourcing functions shared service centres external providers roche finance report financial review roche group diagnostics division strategy plans diagnostics division incurred costs chf million mainly employeerelated matters expenses process optimisation plans chf million site consolidation costs pharmaceuticals divisions strategic realignment manufacturing network chf million mainly related exit manufacturing site clarecastle ireland expected costs environmental remediation clarecastle site reassessed resulted increase provisions chf million employeerelated costs chf million recorded redesign manufacturing south san francisco site costs resourcing flexibility plan biologics manufacturing network chf million included closure manufacturing plant rio de janeiro brazil global restructuring plans initiatives pharmaceuticals division incurred costs chf million mainly employee related major items chf million plans outsourcing functions shared service centres external providers chf million chugai total global restructuring costs chf billion details given note annual financial statements impairment goodwill intangible assets pharmaceuticals division pharmaceuticals division recorded impairment charges intangible assets chf million impairment charges chf million related full partial impairments five different compounds due either clinical data assessments decisions stop development respective compounds charge chf million related full impairment compound purchased separately driven change development plan impairment charges chf million related partial impairment compound developed together alliance partner mainly driven reduced revenue forecasts diagnostics division diagnostics division recorded impairment charges chf million major part charge chf million partial writeoff goodwill related diabetes care business impairment result revised market assumptions related blood glucose monitoring area slower expected growth parts business molecular diagnostics business charge full impairment chf million product intangible assets acquired part geneweave acquisition main factors leading updated assumptions timelines research development expenses production costs addition impairment chf million sequencing business full writeoff product intangible assets acquired part ariosa acquisition mainly due change timelines launch related sequencing products impairment charges chf billion pharmaceuticals division largest item charge chf billion relating goodwill intangible assets intermune acquisition diagnostics division recorded impairment charges chf billion major part sequencing business details given notes annual financial statements legal environmental cases based development various litigations notably avastinlucentis investigations meso case net increase provisions chf million major element expenses legal cases chf million expected costs environmental remediation clarecastle site ireland reassessed resulted increase provisions significant developments affecting financial results details given note annual financial statements net income earnings per share ifrs net income increased chf terms cer diluted eps increased chf terms cer core net income increased core eps increased cer core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets income impacts accounting merger acquisition transactions alliance arrangements amount net income attributable noncontrolling interests increased due increased contribution chugai overall group results roche finance report roche group financial review net income change change chf chf chf cer ifrs net income reconciling items net tax global restructuring plans intangible asset amortisation goodwill intangible asset impairment mergers acquisitions alliance transactions legal environmental cases pension plan settlements transitional effect changes us tax rates transitional effect swiss tax reform normalisation equity compensation plan tax benefit core net income supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position financial position change change chf chf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt lease liabilities pensions income taxes nonoperating assets net total net assets compared start year swiss franc appreciated euro us dollar negative translation impact net operating assets partly offset group level natural hedge groups us dollardenominated debt exchange rates used given roche finance report financial review roche group pharmaceuticals division net working capital decreased cer mainly due higher rebate chargeback accruals excluding net trade working capital pharmaceuticals division lower decrease inventories due writeoffs lower inventories mature products trade receivables increased due underlying sales growth longterm net operating assets increased largely due spark therapeutics acquisition initial purchase price allocation added chf billion goodwill diagnostics division increases net working capital net trade working capital driven increase trade receivables due growth sales increase inventories due quality issues increase instruments pending placement longterm net operating assets decreased following impairment charges goodwill intangible assets decrease net debt due free cash flow chf billion partly offset dividend payments chf billion net cash payments chf billion spark therapeutics acquisition led reduction gross debt chf billion chf billion end net pension liability higher chf billion following decreases discount rates net deferred tax assets increased mainly due swiss tax reform impairment intangible assets equity compensation plans resolution tax disputes reduced current tax liabilities lease liabilities chf billion result accounting changes ifrs brought operating leases onto balance sheet effective january free cash flow free cash flow change change chf chf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid free cash flow see pages definition free cash flow detailed breakdown groups operating free cash flow chf billion increase cer due higher cash generation pharmaceuticals business partly offset higher investments intangible assets net working capital lower due increases accruals rebates chargebacks reduction net trade working capital pharmaceuticals division free cash flow chf billion increase cer due higher operating free cash flow partly offset higher tax payments roche finance report roche group financial review pharmaceuticals division operating results pharmaceuticals division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results see pages definition free cash flow roche finance report financial review roche group sales overview pharmaceuticals division sales therapeutic area change sales sales chf chf cer oncology immunology neuroscience ophthalmology haemophilia infectious diseases therapeutic areas total sales sales pharmaceuticals division chf billion increase cer new product sales compensated biosimilar competition mabtherarituxan herceptin avastin china reported continuously strong growth due broader market penetration sales growth driven continuing rollout new products ocrevus hemlibra tecentriq perjeta together contributed additional chf billion cer new sales representing divisions growth ocrevus particular continued high growth development total sales reaching chf billion chf billion due continuing growth us continuing uptake markets notably germany italy launch rollout hemlibra continued sales reaching chf billion across regions tecentriq sales grew regions mostly due higher demand us launches japan italy spain germany france perjeta sales chf billion growth across regions biosimilar competition negative impact year estimated chf billion sales mabtherarituxan herceptin fell chf billion cer europe japan us first biosimilar versions herceptin avastin mabtherarituxan came market second half estimated impact chf billion sales first biosimilar versions avastin registered japan late limited impact sales far total avastin mabtherarituxan herceptin sales chf billion decrease chf billion cer oncology therapeutic area grew led new products tecentriq perjeta kadcyla sales increased growth across regions mainly us due launch new indication avastin sales grew mainly china due broader market penetration across us despite launch biosimilar mid herceptin sales fell affected biosimilar competition europe japan us mabtherarituxan sales decreased due biosimilar pressure europe japan launches first biosimilar mabtherarituxan us late limited impact sales far alecensa showed continuing postlaunch growth across regions sales immunology grew actemraroactemra esbriet increasing respectively mabtherarituxan sales increased driven us lucentis sales grew us approved indications infectious diseases sales higher mainly due higher rocephin sales china partly offset lower sales valcytecymevene us europe due generic competition therapeutic areas sales activasetnkase grew us roche finance report roche group financial review product sales pharmaceuticals division sales change sales sales chf chf cer oncology avastin herceptin mabtherarituxan perjeta tecentriq kadcyla alecensa gazyvagazyvaro xeloda tarceva others total oncology immunology actemraroactemra xolair mabtherarituxan esbriet pulmozyme cellcept others total immunology neuroscience ocrevus madopar others total neuroscience ophthalmology lucentis total ophthalmology haemophilia hemlibra total haemophilia infectious diseases tamiflu rocephin others total infectious diseases therapeutic areas activasetnkase mircera neorecormonepogin others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology therapeutic areas roche finance report financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl rheumatoid arthritis ra well certain types antineutrophil cytoplasmic antibody ancaassociated vasculitis mabtherarituxan regional sales change sales sales chf chf cer united states europe japan international total sales sales lower due launch biosimilars europe japan us sales increased growth oncology therapeutic area driven subcutaneous formulation also immunology first biosimilar version mabtherarituxan launched us november limited impact sales far sales international region lower due competitive pressures across various countries partially offset growth china due broader market penetration franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sales change sales sales chf chf cer united states europe japan international total sales perjeta regional sales change sales sales chf chf cer united states europe japan international total sales kadcyla regional sales change sales sales chf chf cer united states europe japan international total sales sales franchise grew chf billion herceptin sales lower mainly driven europe partially offset growth china sales increased due broader market penetration decline europe mainly due biosimilar launches mid us herceptin sales lower part due patients switching kadcyla showed growth us part due launch first us biosimilar july sales perjeta grew increased demand regions notably early breast cancer adjuvant setting kadcyla sales increased globally due launch new indication roche finance report roche group financial review avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma avastin regional sales change sales sales chf chf cer united states europe japan international total sales overall sales increased compared prior year us continued sales growth approved indications us sales growing first six months impacted launch first us biosimilar july europe sales higher mainly driven germany international region sales grew largely due broader market penetration china sales increased japan sales remained stable launches biosimilar versions avastin japan late limited impact sales far actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth regions driven uptake subcutaneous formulation us major contributor sales increase along japan xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sales change sales sales chf chf cer united states total sales sales grew driven demand growth chronic idiopathic urticaria expansion overall asthma market xolair remains market leader allergic asthma indication ocrevus relapsing forms multiple sclerosis rms primary progressive multiple sclerosis ppms ocrevus regional sales change sales sales chf chf cer united states europe international total sales continuously growing demand indications us growth driven new returning patients europe international region ocrevus continues show strong uptake launched notably germany italy spain uk roche finance report financial review roche group lucentis wet agerelated macular degeneration wet amd macular oedema following retinal vein occlusion rvo diabetic macular oedema dme diabetic retinopathy dr lucentis regional sales change sales sales chf chf cer united states total sales us sales grew driven increased market share across indications ongoing rollout prefilled syringes tecentriq advanced bladder cancer advanced lung cancer initial therapy nonsquamous nonsmall cell lung cancer nsclc extensivestage small cell lung cancer pdlpositive triplenegative breast cancer tecentriq regional sales change sales sales chf chf cer united states europe japan international total sales sales grew growth regions notably us higher sales driven new indications extensivestage small cell lung cancer pdlpositive triplenegative breast cancer europe sales grew mainly due launches italy spain germany sales japan increased due growth treatment nonsquamous nsclc hemlibra haemophilia hemlibra regional sales change sales sales chf chf cer united states europe japan international total sales hemlibra first approved sale us food drug administration fda november since launched regions us sales grew due broader market penetration strong demand severe noninhibitor patients activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sales change sales sales chf chf cer united states international total sales sales higher led us mainly driven broader use hospitals higher number patients treated roche finance report roche group financial review esbriet idiopathic pulmonary fibrosis ipf esbriet regional sales change sales sales chf chf cer united states europe international total sales sales grew continued growth across europe us international europe sales increased driven growth italy spain pharmaceuticals division sales region change sales sales chf chf cer united states europe japan international total sales united states sales grew led ocrevus hemlibra tecentriq ocrevus sales increased driven new returning patient demand hemlibra sales showed strong uptake since launch november tecentriq sales increased mainly driven growth new indications franchise grew sales increase kadcyla due launch new indication increase perjeta especially driven early breast cancer adjuvant setting avastin sales increased due continued growth indications partly offset launch first biosimilars july first biosimilars herceptin also launched mid mabtherarituxan late europe sales grew full year compared decline first six months launch continuous uptake new products compensating impact biosimilars full year herceptin mabtherarituxan sales decreased respectively due competition biosimilars strong growth ocrevus perjeta notably germany tecentriq sales continued grow following launches italy spain continued uptake germany france alecensa sales increased particular france italy germany growth hemlibra sales driven france germany italy uk japan sales increased driven new products including hemlibra tecentriq gazyvagazyvaro launched franchise grew sales increase perjeta due launch new indication growth partially offset lower sales mabtherarituxan xeloda tarceva herceptin negatively affected competing products biosimilars generics sales avastin remained stable launches biosimilar versions avastin japan late limited impact sales international sales increased mainly due growth china broader market penetration herceptin avastin mabtherarituxan new launches perjeta alecensa sales china towards end impacted reduction level channel inventory growth russia driven inclusion perjeta kadcyla national oncology program well launch tecentriq excluding china russia sales rest international region increased growth new products perjeta ocrevus tecentriq kadcyla offsetting decline herceptin mabthera rituxan roche finance report financial review roche group pharmaceuticals division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales competition generic medicines biosimilars groups pharmaceutical products generally protected patent rights intended provide group exclusive marketing rights various countries however patent rights varying scope duration group may required enter costly litigation enforce patent intellectual property rights loss market exclusivity one major products either due patent expiration challenges generic medicines biosimilars noncomparable biologics reasons could material adverse effect groups business results operations financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically results significant reduction net sales relevant product manufacturers typically offer versions lower prices patents expiry always integral part groups business model future growth remain driven innovation latest information clinical studies included annual report pages details groups product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm product sales affected recent patent expiry change chf chf cer comment tarceva patent expiry us intellectual property biologics involve multiple patents patent timelines individual product therefore difficult give exact date patent expiry biologic medicines basic primary patents groups major biologic medicines begin expire follows mabtherarituxan us herceptin us avastin us eu subcutaneous formulations mabtherarituxan herceptin beyond secondary patent rights biosimilar competition three products estimated negative impact chf billion main impact sales mabtherarituxan herceptin fell chf billion cer europe japan united states first biosimilar versions herceptin avastin launched us mid first biosimilar versions mabtherarituxan late estimated impact sales chf billion europe first biosimilar versions mabtherarituxan launched europe mid marketed eu countries major factor sales decline product europe first biosimilar versions herceptin launched major eu markets mid based publicly available information competitor companies group currently anticipates first biosimilar versions avastin could come market europe first half japan japan first biosimilar versions mabtherarituxan herceptin launched sales impacted government price cuts first biosimilar version avastin launched late colorectal cancer setting roche finance report roche group financial review product sales affected biosimilar launches change chf chf cer comment mabtherarituxan us first biosimilar launches late herceptin us first biosimilar launches mid avastin us first biosimilar launches mid mabtherarituxan europe first biosimilar launches mid herceptin europe first biosimilar launches mid avastin europe biosimilar launches end mabtherarituxan japan first biosimilar launches early herceptin japan first biosimilar launches mid avastin japan first biosimilar launches late colorectal cancer indication sales mabtherarituxan herceptin avastin disclosed previous sections including regional breakdowns summarised table noted previous sections yearonyear movements also driven regular price volume changes biosimilar competition one factor overall picture total mabtherarituxan herceptin avastin sales change division sales division sales chf chf cer united states europe japan international total sales group derives royalty income us patent known cabilly patent patent expired december residual income expiry chf million annual royalty income patent chf million operating results pharmaceuticals division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis royalties operating income decreased cer royalty income lower mainly due expiry cabilly patent end income related patent decreased chf million chf million outlicensing income lower due base effect higher milestone income income product disposals increased chf million driven income chf million sale rights lexotan bactrim dormicum higher profitshare income chf million increased venclexta xolair sales roche finance report financial review roche group pharmaceuticals division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales cost sales decreased percentage points manufacturing cost sales grew sales growth volumedriven manufacturing cost increase partially offset favourable product mix lower inventory writeoffs royalty expenses higher due increased sales certain products notably ocrevus impairment property plant equipment idle plant recognised noncore costs include amortisation intangible assets mainly related esbriet product intangible assets acquired intermune acquisition amortisation charges higher esbriet product intangible assets since previous impairments partially reversed end pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales decrease percentage points major marketing distribution activities included supporting launches rollouts tecentriq ocrevus xofluza supporting prelaunch activities cost increase also associated rampup marketing activities personalised health care foundation medicine flatiron health strategic businesses restructuring costs related resourcing flexibility initiatives sales affiliates pharmaceuticals division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales decreased percentage points oncology franchise remained largest area research development cancer immunotherapy portfolio key driver neuroscience immunology also represent significant areas spending addition pharmaceuticals division inlicensed pipeline compounds technologies capitalised intangible assets total cost chf billion chf billion usd million initial upfront payments adaptive biotechnologies dicerna pharmaceuticals impairment charges chf million incurred impairment different compounds due either clinical data assessments decisions stop development respective compounds roche finance report roche group financial review pharmaceuticals division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pensions settlement gains losses total ifrs basis core costs increased cer percentage sales stable administration costs higher mainly due increases foundation medicine base effect flatiron health acquired april legal environmental charges higher due increase provisions related avastinlucentis investigations increase provision environmental remediation clarecastle site impairment charges related full writeoff goodwill intermune trophos acquisitions roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales external customers pharmaceuticals division total core operating profit operating profit include elimination chf minus million unrealised intercompany gains roche pharmaceuticals chugai chf minus million increase exchange rate japanese yen positive impact approximately chugai results expressed swiss francs groups consolidated results cer reported japanese yen sales chugai external customers increased sales within division increased chugai core operating profit increased due higher royalty income roche pharmaceuticals well higher gross profit sales external customers sales within division partially offset lower income divestment established products higher research development costs operating free cash flow chugai increased result strong operating performance lower capital expenditures due base effect land purchase yokohama japan roche finance report financial review roche group financial position pharmaceuticals division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment rightofuse assets goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given pages currency translation effects balance sheet amounts compared start year swiss franc appreciated us dollar resulting negative translation impact net operating assets exchange rates used given net working capital net working capital decreased due higher net liability receivablespayables net trade working capital lower trade receivables higher following underlying sales growth business inventories decreased primarily due writeoffs lower inventory levels certain mature products increase trade payables mainly due outstanding usd million upfront payment due dicerna pharmaceuticals net liability position receivablespayables increased mainly due higher accruals rebates chargebacks longterm net operating assets overall longterm net operating assets increased largely due spark therapeutics acquisition initial purchase price allocation added chf billion goodwill increase chf billion rightofuse assets implementation ifrs beginning year increase provisions mainly attributable ongoing litigations restructuring activities capital expenditure includes investments basel kaiseraugst site switzerland south san francisco campus us manufacturing investments switzerland us japan germany well expenditure new research facilities yokohama japan roche finance report roche group financial review free cash flow pharmaceuticals division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow sales see pages definition free cash flow detailed breakdown pharmaceuticals divisions operating free cash flow increased cer chf billion operating profit net operating cash adjustments increased line core operating profit growth net working capital lower due reductions net trade working capital reasons described financial position section increase accruals rebates chargebacks capital expenditure lower due base effect yokohama land purchase final payment genentech property lease option exercise investments intangible assets higher include usd million initial upfront payment adaptive biotechnologies roche finance report financial review roche group diagnostics division operating results diagnostics division operating results change change chf chf chf cer ifrs results sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income revenue cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results see pages definition free cash flow sales diagnostics division sales business area change sales sales chf chf cer centralised point care solutions molecular diagnostics diabetes care tissue diagnostics total sales diagnostics division reported sales growth cer chf billion centralised point care solutions led immunodiagnostics business sales growth mainly due china emerging markets molecular diagnostics sales increased growth underlying molecular business diabetes care sales increased driven higher sales north america partially offset price pressure europe middle east africa emea region sales tissue diagnostics stable due higher sales advanced staining reagents offset lower instrument sales roche finance report roche group financial review centralised point care solutions regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales increase sales centralised point care solutions business area major contributor divisional performance growth primarily driven immunodiagnostics business due instrument launches ongoing rollouts mainly china us south korea partially offset decline coagulation monitoring sales north america molecular diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales overall molecular diagnostics sales rose growth underlying molecular business well increase sequencing business regional growth led asiapacific mainly china emea sales growth molecular business came increased demand blood screening grew mainly us china germany diabetes care regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales diabetes care sales increased led north america due growth accuchek guide product line emea decline due price pressure germany uk italy tissue diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales tissue diagnostics sales stable higher sales advancedstaining reagents offset lower sales due delays shipment instruments regionally decline sales north america asiapacific sales increased china main growth market roche finance report financial review roche group diagnostics division sales region change sales sales chf chf cer europe middle east africa emea asiapacific north america latin america japan total sales immunodiagnostics business centralised point care solutions global driver sales growth sales increase asiapacific mainly china south korea following increased reagent sales installed instruments partly offset reduction channel inventory china north america sales stable due higher sales blood glucose monitoring immunodiagnostics offset decline coagulation monitoring business diagnostics division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales operating results diagnostics division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products royalties operating income core basis global restructuring plans total ifrs basis core royalties operating income increased cer driven higher royalty income due settlement royalty dispute diagnostics division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer sales growth due higher costs external suppliers increased costs technical engineering services royalty expenses significantly lower result renegotiation licensing agreement core cost sales ratio increased percentage points global restructuring costs increased due strategy plans amortisation intangible assets lower following impairments intangible assets recognised second half impairment charges related intangible assets molecular diagnostics sequencing businesses roche finance report roche group financial review diagnostics division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs stable cer due higher marketing expenses digital solutions business offset lower bad debt expenses regionally higher spending asiapacific offset lower expenses europe north america core basis marketing distribution costs percentage sales decreased compared increase global restructuring plan cost relates transformation projects affecting sales force diagnostics division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer due spending new projects cardiac disease within centralised point care solutions portfolio well increased spending laboratory automation partly offset lower spending development projects notably molecular diagnostics diabetes care percentage sales research development core costs stable global restructuring costs due strategy plans impairment charges related intangible assets sequencing business diagnostics division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment gains losses disposal divestment subsidiaries business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases total ifrs basis core costs decreased cer due gain property disposal administration costs stable due cost containment initiatives business taxes higher due base effect settlement agreement medical device excise tax us percentage sales core costs decreased impairment charges chf million partial writeoff goodwill related diabetes care business mergers acquisitions alliance transactions include income reversal contingent consideration provisions legal environmental costs included litigation costs meso case roche finance report financial review roche group financial position diagnostics division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivables payables net working capital property plant equipment rightofuse assets goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given pages currency translation effects balance sheet amounts compared start year swiss franc appreciated euro us dollar resulting negative translation impact net operating assets exchange rates used given net working capital net working capital increased net trade working capital increased increases mainly attributable trade receivables inventories increased respectively trade receivables increased due growth sales change distributor channels middle east increase inventories due quality issues increase instruments pending placement longterm net operating assets overall longterm net operating assets decreased cer mainly result impairment goodwill intangible assets rightofuse assets recorded result implementation ifrs provisions increased due higher litigation restructuring provisions partially offset reversal contingent consideration provisions capital expenditure relates instrument placements manufacturing expansion projects germany site consolidation project us roche finance report roche group financial review free cash flow diagnostics division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow sales definition free cash flow detailed breakdown see pages operating free cash flow diagnostics division net cash inflow chf million decrease cer compared cash generation business measured operating profit net operating cash adjustments stable compared increase core operating profit difference due higher cash spending restructuring litigation cases net working capital movement absorbed chf million cash due increases inventories trade receivables mentioned financial position comments capital expenditure chf billion due items mentioned financial position section increased spending relative driven site consolidation project us chf million investments intangible assets mainly related inlicensing deal chf million roche finance report financial review roche group corporate operating results corporate operating results summary change chf chf cer administration pensions past service costs business taxes capital taxes general items general administration costs core basis global restructuring plans legal environmental cases total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results see pages definition free cash flow detailed breakdown general administration costs increased cer core basis driven higher projectrelated administration costs corporate functions lower restructuring costs came reduction restructuring activities procurement net working capital lower due higher payables change longterm net operating assets largely attributable rightofuse assets recorded following implementation ifrs corporate operating free cash flow showed higher outflow due settlement payables roche finance report roche group financial review foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer chf change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy results expressed swiss francs negatively impacted stronger swiss franc average euro latin american currencies partly offset appreciation us dollar swiss franc percentage point net impact sales core operating profit expressed swiss francs compared constant exchange rates percentage point net impact core eps sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact increase average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro cost sales marketing administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yen roche finance report financial review roche group treasury taxation results treasury taxation results change change chf chf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position net debt lease liabilities pensions income taxes equity investments derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury activities taxes paid total see pages definition core results see pages definition free cash flow financing costs core financing costs chf million increase cer compared due losses early debt redemption chf million none interest expenses including amortisation debt discount issue costs remained stable chf million net interest cost defined benefit pension plans chf million full analysis financing costs given note annual financial statements roche finance report roche group financial review financial income expense core financial income expense net income chf million compared net income chf million net income equity securities gain chf million driven unrealised gains roche venture fund investment allakos compares net gain chf million group realised gain sale avexis shares chf million well unrealised gains allakos net foreign exchange results reflect hedging costs losses unhedged positions losses chf million compared net losses chf million full analysis financial income expense given note annual financial statements income taxes groups effective core tax rate decreased percentage points mainly due impacts resolution several tax disputes tax disputes resolved first half additional unrelated tax disputes resolved second half resulted positive income statement impact chf million equivalent percentage points effective core tax rate full year ifrs results saw effective tax rate decrease percentage points addition core impacts mentioned lower goodwill impairments noncore impacts swiss tax reform described deferred tax impact equity compensation plans decreased ifrs tax rate ifrs results also include releases contingent consideration provisions taxable hence net effect mergers acquisitions alliance transactions line table switzerland changes swiss federal canton baselstadt tax laws enacted first half relevant changes roche group include decrease baselstadt tax rate effective january new limitations changes reduce groups effective tax rate baselstadt changes tax laws swiss cantons group operates enacted second half group carried remeasurement deferred tax positions resulted transitional deferred tax income chf million reported noncore item impact tax payments details groups income tax expenses related balance sheet positions given note annual financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate chf chf chf chf groups effective tax rate core basis global restructuring plans goodwill intangible assets mergers acquisitions alliance transactions legal environmental cases pension plan settlements transitional effect changes us tax rates transitional effect swiss tax reform normalisation equity compensation plan tax benefit groups effective tax rate ifrs basis financial position decrease net debt mainly due free cash flow chf billion partly offset dividend payments chf billion net cash payments chf billion spark therapeutics acquisition net pension liability increased due lower discount rates net deferred tax assets increased mainly due swiss tax reform impairment intangible assets equity compensation plans resolution tax disputes reduced current tax liabilities december group held equity investments market value chf billion consist mostly holdings biotechnology pharmaceuticals companies acquired part licensing transactions scientific collaborations investments roche venture fund roche finance report financial review roche group free cash flow net cash outflow treasury activities decreased chf billion total taxes paid chf billion due higher payments us partly offset refunds received resolution several tax disputes cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment principal portion lease liabilities paid investments intangible assets operating free cash flow treasury activities taxes paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid free cash flow definition free cash flow detailed breakdown see pages operating free cash flow increased cer chf billion due higher growth underlying cash generated operations cash revenues grew cash expenses partly offset higher investments intangible assets free cash flow chf billion higher result higher operating free cash flow partly offset higher tax payments roche finance report roche group financial review effective january group implemented ifrs leases comparative results restated main impact new standard bring operating leases onto balance sheet application new standard materially impact operating free cash flow repayment principal portion lease liabilities paid presentation almost entirely matches operating lease expenses included operating profit presentation net debt unaffected groups definition net debt include lease liabilities net debt millions chf january cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow dividend payments transactions equity instruments mergers acquisitions net divestments subsidiaries hedging collateral arrangements changes ownership interests subsidiaries currency translation fair value movements change net debt december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period definition net debt see net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swapped us dollars therefore consolidated results economic characteristics equivalent us dollardenominated bonds notes net debt position group december chf billion reduction chf billion december reduction gross debt chf billion total chf billion end driven free cash flow chf billion partly offset annual dividend payments chf billion net cash payments chf billion spark therapeutics acquisition roche finance report financial review roche group contractual obligations commitments group obligations commitments set table carrying values shown consolidated balance sheet potential obligations shown discounted riskadjusted amounts denominated foreign currencies translated swiss francs december exchange rates contractual obligations commitments december millions chf potential obligation undiscounted less carrying year years years years total value onbalance sheet debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities unfunded defined benefit plans total onbalance sheet commitments offbalance sheet capital commitments property plant equipment leasing commitments contract manufacturing commitments alliance collaboration commitments total offbalance sheet commitments total contractual commitments references notes annual financial statements debt consists mainly bonds notes includes principal interest groups debt instruments debt mainly commercial paper carrying values discounted based interest rates inherent instruments contingent consideration potential payments arising mergers acquisitions carrying values riskadjusted discounted lease liabilities future obligations noncancellable lease contracts group implemented ifrs leases effective january since point obligations reported balance sheet unfunded defined benefit plans mainly pension plans groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations carrying values discounted future company contributions groups funded plans shown table capital commitments property plant equipment noncancellable commitments purchase construction mainly roche sites basel switzerland south san francisco us mannheim germany also chugai site yokohama leasing commitments major noncancellable commitments signed lease agreements lease term yet started mainly relate foundation medicines site boston us contract manufacturing commitments future minimum takeorpay commitments purchase inventories arising groups major longterm agreements external contract manufacturing organisations cmos roche finance report roche group financial review alliance collaboration commitments potential upfront milestone payments may become due groups inlicensing arrangements potential payments alliance partners asset deals within next three years included assuming projects currently development successful potential payments beyond three years included asset deals provisions legal environmental matters included table timing amount cash outflow uncertain contingent development matters question pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources expenses groups defined benefit plans chf million chf million defined benefit plans funding status balance sheet position chf chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups funded defined benefit plans decreased compared start year came mainly decrease discount rates globally since end largely offset increase fair value plan assets switzerland us funded status pension funds monitored local pension fund governance bodies well closely reviewed group level total cash outflow groups defined benefit plans chf billion compared chf billion higher additional contributions paid groups pension plans japan us unfunded plans mainly groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations unfunded liabilities plans increased due decrease eurozone discount rate full details groups pensions postemployment benefits given note annual financial statements roche finance report financial review roche group roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates cer roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group chf terms cer strong growth pushed world equity markets record highs growth swiss market index smi outperformed major european indices slightly trailed major us indices global healthcare sector grew strongly well roche outperformed peers chf terms swiss market index positive news flow strong sales growth driven new products peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche finance report roche group financial review proposed dividend board directors proposing increase dividend chf per share nonvoting equity security chf approval annual general meeting would rd consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion chf billion resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security also information roche securities given pages information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes annual financial statements payout ratio calculated dividend per share divided core earnings per share roche finance report financial review roche group debt debt repayments following scheduled debt repayments due date september usd billion bonds december usd billion bonds repaid option issuer par months scheduled due date march debt redemptions december group completed tender offer redeem following instruments usd million fixed rate notes due september usd million fixed rate notes due september usd million fixed rate notes due september usd million fixed rate notes due november usd million fixed rate notes due july usd million fixed rate notes due march early debt redemption resulted total payment usd million reported loss redemption chf million debt issuances debt issuances transactions described note annual financial statements maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf beyond total total translated december exchange rates proceeds bonds notes eur million swapped us dollars therefore consolidated results bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow chf billion included cash generated operations well payment interest tax shortterm financing requirements group commercial paper program us issue usd billion unsecured commercial paper notes committed credit lines usd billion available backstop lines commercial paper notes totalling usd billion outstanding december usd billion longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors aa moodys facilitate efficient access international capital markets information groups debt given note annual financial statements roche finance report roche group financial review financial risks december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt repayment liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities chf total chf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups chf billion cash fixed income marketable securities remained strong invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables chf billion since beginning financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables eur billion chf billion public customers countries increase compared december euro terms group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions since groups trade receivables balance southern europe decreased euro terms liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group strong cash generation ability future cash flows used repay debt instruments coming years roche enjoys strong longterm investmentgrade credit ratings aa standard poors aa moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings strong credit roche permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling usd billion available backstop lines commercial paper program december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var decreased since december mainly due repayment early redemption longterm debt second half well due reduction underlying interest rates across major group currencies interest rate risk interest rate risk arises movements interest rates could affect groups financial result value group equity group may use interest rate derivatives manage interest raterelated exposure financial result information financial risk management financial risks var methodology included note annual financial statements roche finance report financial review roche group international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented ifrs leases including consequential amendments standards group also implemented various minor amendments existing standards interpretations including ifric uncertainty income tax treatments material impact groups overall results financial position new revised standards applied ifrs leases group implemented new standard effective january applied cumulative catchup method option transition meaning comparative results restated main impact new standard bring operating leases onto balance sheet new standard results carrying value leased assets rightofuse assets increasing chf billion january lease liabilities increasing similar amount application new standard resulted part previously reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group currently expect effect material amount chf million see note annual financial statements details roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative income statement year ended december restated changes material impact income statement see note roche finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income revenue cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative income statement year ended december restated changes material impact income statement see note roche finance report roche group roche group consolidated financial statements roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income oci remeasurements defined benefit plans fair value changes equity investments fair value oci items never reclassified income statement fair value changes debt securities fair value oci cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative statement comprehensive income year ended december restated changes material impact statement comprehensive income see note roche finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment rightofuse assets goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative balance sheets december december restated transition impact details additional assets liabilities reported effective january provided note roche finance report roche group roche group consolidated financial statements roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations asset acquisitions divestment subsidiaries interest dividends received sales equity securities debt securities purchases equity securities debt securities sales purchases money market instruments time accounts three months net investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements changes ownership interest subsidiaries equity contribution noncontrolling interests interest paid principal portion lease liabilities paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative statement cash flows year ended december restated finance lease liabilities paid included increase decrease debt roche finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january revised net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december year ended december january implementation ifrs leases january revised net income recognised income statement net change fair value financial assets fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative statement changes equity year ended december restated details additional assets liabilities reported effective january provided note equity january revised following implementation ifrs financial instruments roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist various performance obligations satisfied different times contracts entered diagnostics division typically include performance obligations instruments including provided leasing arrangements reagents consumables services instruments may sold cash sales transactions discounted prices instruments provided operating lease arrangements entire lease revenue may variable subject subsequent reagents sales sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing may settled combination upfront payments milestone payments licensing fees reimbursements services provided whether consider commitments single performance obligation separate ones even scope ifrs revenues contracts customers straightforward requires judgement depending conclusion may result revenue calculated inception either recognised spread term longer performance obligation sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries provisions accruals relating us pharmaceuticals business amounted chf million chf million associated expected sales returns estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustment roche finance report notes roche group consolidated financial statements roche group business combinations group initially recognises fair value identifiable assets acquired liabilities assumed non controlling interest consideration transferred business combination management judgement particularly involved assessment whether net assets acquired constitute business recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms management also applies considers appropriate optional concentration test set amendments ifrs business combinations published october aid assessment whether transaction represents business combination simply substance purchase single asset group similar assets impairment property plant equipment rightofuse assets goodwill intangible assets december group chf million property plant equipment see note chf million rightofuse assets see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment rightofuse assets intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lowerthananticipated product sales could lead shorter useful lives impairment impairment financial assets december group chf million allowance doubtful accounts trade lease receivables see note allowance doubtful accounts based assumptions risk default expected loss rates group uses judgement making assumptions selecting inputs calculation allowance doubtful accounts based companys past experience existing market conditions well forwardlooking estimates end reporting period pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter lifespans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated reliable estimate made provision recorded contingent liabilities disclosed material december group chf million legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions see note total potential payments contingent consideration arrangements business combinations could chf million see note estimated amounts provided expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops roche finance report roche group notes roche group consolidated financial statements income taxes december group current income tax net liability chf million deferred tax net asset chf million see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations tax positions uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases group lessee key judgements include assessing whether arrangements contain lease determining lease term assess whether contract contains lease requires judgement whether depends specified asset whether group obtains substantially economic benefits use asset whether group right direct use asset order determine lease term judgement required extension termination options assessed along facts circumstances may create economic incentive exercise extension option exercise termination option estimates include calculating discount rate based incremental borrowing rate december group chf million rightofuse assets chf million lease liabilities see note group lessor treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms roche finance report notes roche group consolidated financial statements roche group operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes legal safety environmental services subdivisional information also presented roche pharmaceuticals chugai operating segments within pharmaceuticals division divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions rightofuse assets additions intangible assets total research development research development costs segment information depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets equity compensation plan expenses roche finance report roche group notes roche group consolidated financial statements pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination results within division operating profit capital expenditure business combinations asset acquisitions additions property plant equipment additions rightofuse assets additions intangible assets total research development research development costs elimination costs within division total segment information depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets equity compensation plan expenses roche finance report notes roche group consolidated financial statements roche group net assets millions chf assets liabilities net assets december net operating assets pharmaceuticals diagnostics corporate total current income tax net assets liabilities deferred tax net assets liabilities defined benefit plan net assets liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities total net assets net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets december roche pharmaceuticals chugai elimination within division pharmaceuticals division roche finance report roche group notes roche group consolidated financial statements information geographical area millions chf revenues external customers noncurrent assets royalties property plant rightofuse goodwill sales operating income equipment assets intangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue following implementation ifrs leases see note group changed accounting policies respect leases group applied cumulative catchup method transition meaning comparative results restated roche finance report notes roche group consolidated financial statements roche group operating segment disclosures main impact new standard include rightofuse assets leases group lessee previously reported operating leases part segment operating assets effective january details additional segment net operating assets reported total chf million given transition impact ifrs segment net operating assets millions chf january assets liabilities net assets roche pharmaceuticals chugai pharmaceuticals division diagnostics division corporate total operating lease liabilities group consequence application new standard interest element leases previously reported operating lease reported part operating lease costs within segment results recorded interest expenses effective january given leases involved prevailing low interest rate environment group currently expect effect material amount chf million major customers total three us national wholesale distributors represent approximately third groups revenues three us national wholesale distributors mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenues roche pharmaceuticals operating segment residual diagnostics operating segment roche finance report roche group notes roche group consolidated financial statements revenue disaggregated revenue information disaggregation revenue millions chf revenue revenue contracts revenue contracts revenue customers sources total customers sources total pharmaceuticals division sales therapeutic area oncology immunology neuroscience ophthalmology haemophilia infectious diseases therapeutic areas sales royalty income income outlicensing agreements income disposal products royalties operating income diagnostics division sales business area centralised point care solutions molecular diagnostics diabetes care tissue diagnostics sales royalty income income outlicensing agreements income disposal products royalties operating income total revenue sources primarily relates lease revenue collaboration income counterparty considered customer income profitsharing arrangements roche finance report notes roche group consolidated financial statements roche group grosstonet sales reconciliation pharmaceuticals division grosstonet sales reconciliation pharmaceuticals division shown table companies diagnostics division similar reconciling items much lower amounts pharmaceuticals division sales grosstonet reconciliation millions chf gross sales government regulatory mandatory price reductions contractual price reductions cash discounts customer returns reserves others net sales government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us totalled usd billion equivalent chf billion usd billion equivalent chf billion contractual price reductions include rebates chargebacks result contractual agreements primarily volume based performance based cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables see note sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities see note provisions sales returns recorded balance sheet provisions see note contract balances receivables millions chf accounts receivable current receivables contracts customers noncurrent receivables contracts customers total receivables current receivables mainly include royalty licensing receivables december total receivables include lease receivables considered receivables contracts customers contract assets millions chf accrued income total contract assets roche finance report roche group notes roche group consolidated financial statements contract liabilities millions chf deferred income noncurrent deferred income current total contract liabilities movement contract liabilities millions chf january business combinations revenue recognised included contract liability balance beginning year increases due cash received receivable excluding amounts recognised revenue year divestment subsidiaries currency translation effects december revenue recognised relation performance obligations satisfied previous years increase revenue recognised chf million increase chf million relating performance obligations satisfied previous periods mainly due adjustments sales deduction provisions accruals expected sales returns chargebacks allowances respect previous years remaining performance obligations partially unsatisfied longterm contracts remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing noncancellable otherwise enforceable contracts mainly associated contracts diagnostics division minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales transaction price allocated contracts partially unsatisfied performance obligations millions chf contract liability held contract liability held total thereof expected recognised revenue within one year one five years five years total roche finance report notes roche group consolidated financial statements roche group net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses redemption repurchase bonds notes discount unwind net interest cost defined benefit plans interest expense lease liabilities total financing costs financial income expense millions chf net gains losses equity investments securities fair value profit loss dividend income equity investments securities fair value profit loss dividend income equity investments securities fair value oci net income equity investments securities interest income debt securities fair value oci amortised cost net gains losses sale debt securities fair value oci net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses gains losses net monetary position hyperinflationary economies net financial income expense associates total financial income expense net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense disclosed note note following implementation ifrs group changed accounting policies respect leases group applied cumulative catchup method transition meaning comparative results restated application new standard resulted part previously reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group expect effect material amount chf million roche finance report roche group notes roche group consolidated financial statements hyperinflationary economies since july group considered argentina hyperinflationary economy context ias financial reporting hyperinflationary economies cumulative inflation index last three years exceeds measured national wholesaler price index sistema de ndices de precios mayoristas accordingly group reviewed reporting affiliates argentina necessary restated line ias potential adjustments resulting application ias significant impact groups operating results balance sheet adjustment recorded gains losses net monetary position loss chf million resulting loss purchasing power positive net monetary position groups argentinian affiliates loss chf million income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate increased largely due higher proportion groups profits coming tax jurisdictions higher local tax rates average group tax rate groups effective tax rate decreased main drivers decrease resolution several tax disputes resulted positive income statement impact chf million lower goodwill impairments impacts swiss tax reform deferred tax impact equity compensation plans varies according price underlying equities switzerland changes swiss federal canton baselstadt tax laws enacted first half relevant changes group include decrease baselstadt tax rate effective january new limitations changes reduce groups average expected tax rate baselstadt changes tax laws swiss cantons group operates enacted second half group carried remeasurement deferred tax positions impacted net deferred tax liability positions balance sheet reduced chf million deferred tax remeasurement impact tax payments resulted transitional deferred tax income chf million remaining adjustments chf million recorded comprehensive income far relate temporary differences arising items recorded comprehensive income actuarial gainslosses swiss pension plans roche finance report notes roche group consolidated financial statements roche group groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development tax credits deductions us state tax impacts tax unremitted earnings transitional effect changes us tax rates transitional effect swiss tax reform resolution several tax disputes prior year differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans equity investments fair value oci debt securities fair value oci cash flow hedges currency translation foreign operations comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities current income tax liabilities include accruals uncertain tax positions roche finance report roche group notes roche group consolidated financial statements current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december deferred taxes movements recognised net assets liabilities millions chf property plant equipment rightofuse intangible defined temporary assets assets benefit plans differences total year ended december january revised business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january implementation ifrs leases january revised business combinations asset acquisitions charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative balance sheets december december restated deferred tax assets january revised following implementation ifrs financial instruments deferred tax net assets temporary differences mainly relate accrued liabilities including lease liabilities provisions unrealised profit inventory deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable chf tax rate chf tax rate within one year one five years five years total unrecognised tax losses roche finance report notes roche group consolidated financial statements roche group five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested purpose financial statements total unremitted earnings group regarded permanently reinvested purpose financial statements chf billion december chf billion mergers acquisitions group implemented amendments ifrs business combinations issued october amendments clarify definition business effect amendments particularly applicable many acquisitions carried group since value acquired companies often largely consists rights single product technology transactions accounted asset acquisitions rather business combinations note includes transactions accounted business combinations asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations ifrs cash consideration paid asset acquisitions transaction date subsequent additional contingent payments made upon achievement performancerelated development milestones presented line asset acquisitions disclosed separately subsequent consideration performance related development milestones transactions treated asset acquisitions recognised intangible assets specific milestones achieved business combinations spark therapeutics inc december group acquired controlling interest spark therapeutics inc spark therapeutics publicly owned us company based philadelphia pennsylvania listed nasdaq spark therapeutics fully integrated commercial company committed discovering developing delivering gene therapies spark therapeutics reported pharmaceuticals division total consideration usd million paid cash identifiable assets acquired liabilities assumed set table amounts provisional based preliminary information transaction closed shortly end reporting period identification valuation intangible assets assets liabilities adjusted business combinations net assets acquired millions chf spark therapeutics property plant equipment rightofuse assets intangible assets cash cash equivalents marketable securities noncurrent liabilities deferred income lease liabilities longterm liabilities net assets liabilities net identifiable assets goodwill total consideration cash total consideration roche finance report roche group notes roche group consolidated financial statements due provisional accounting apart goodwill intangible assets yet recognised provisional goodwill computed table also represents rights spark therapeutics clinical preclinical assets includes spark therapeutics lead clinical asset spk novel gene therapy treatment haemophilia luxturna spark therapeutics marketed gene therapy treatment patients confirmed biallelic rpe mutationassociated retinal dystrophy inherited retinal disease luxturna first gene therapy receive fda approval european commission granted marketing authorisation luxturna addition goodwill represents spark therapeutics technological capabilities gene therapy remaining goodwill include control premium acquired work force expected synergies none goodwill expected deductible income tax purposes spark therapeutics accounts receivable comprised gross contractual amounts due chf million expected collectable date acquisition directly attributable transaction costs chf million reported roche pharmaceuticals operating segment within general administration expenses impact acquisition results pharmaceuticals division group material acquisition occurred january management estimates spark therapeutics would contributed revenue approximately chf million net loss tax approximately chf million information provided illustrative purposes necessarily indicative results combined group would occurred spark therapeutics actually acquired beginning year indicative future results combined group business combinations flatiron health inc april group acquired controlling interest flatiron health inc flatiron health privately owned us company based new york city flatiron health reported pharmaceuticals division total consideration usd million paid cash identifiable assets acquired liabilities assumed set table business combinations net assets acquired millions chf flatiron health intangible assets product intangibles use marketing intangibles use deferred tax assets cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets fair value previously held interest goodwill total consideration cash total consideration fair value flatiron healths technology platform determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate flatiron health valuation performed independent valuer goodwill represents value accelerating progress towards datadriven personalised healthcare cancer advance use realworld evidence set new industry standards oncology research development also represents control premium acquired work force expected synergies none goodwill expected deductible income tax purposes group recognised financial gain chf million fair valuing interest flatiron health held group prior transaction gain included statement changes equity within line item net change fair value financial assets fair value oci transferred retained earnings upon obtaining control roche finance report notes roche group consolidated financial statements roche group directly attributable transaction costs chf million reported roche pharmaceuticals operating segment within general administration expenses nine months december flatiron health contributed revenue chf million net loss tax chf million results reported pharmaceuticals division group acquisition occurred january management estimates flatiron health would contributed revenue chf million net loss tax chf million information provided illustrative purposes necessarily indicative results combined group would occurred flatiron health actually acquired beginning year indicative future results combined group cash flows business combinations business combinations net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company total net cash outflow directly attributable transaction costs business combinations amounted chf million chf million included cash flow operating activities future asset acquisitions promedior inc november group entered definitive merger agreement fully acquire promedior inc promedior privately owned us company based lexington massachusetts acquisition group obtain rights promediors entire portfolio including phase iiiready asset prm firstinclass recombinant human pentraxin molecule treatment idiopathic pulmonary fibrosis closing transaction currently expected take place first quarter subject expiration termination waiting period hartscottrodino antitrust improvements act closing conditions promedior reported pharmaceuticals division cash consideration paid acquisition date usd million additional contingent payments may made based upon achievement performancerelated milestones asset acquisitions group complete asset acquisitions asset acquisitions ignyta inc february group acquired controlling interest ignyta inc ignyta publicly owned us company based san diego california listed nasdaq ignyta reported pharmaceuticals division total consideration usd million paid cash acquisitions september group acquired controlling interest tusk therapeutics ltd tusk private company based stevenage united kingdom tusk reported pharmaceuticals division november group acquired controlling interest jecure therapeutics inc jecure privately owned us company based san diego california jecure reported pharmaceuticals division total cash consideration paid acquisition date acquisitions chf million additional contingent payments may made based upon achievement performancerelated milestones roche finance report roche group notes roche group consolidated financial statements asset acquisitions net assets acquired millions chf ignyta acquisitions total intangible assets product intangibles available use deferred tax assets cash cash equivalents net assets liabilities net identifiable assets cash total cash consideration cash flows asset acquisitions asset acquisitions net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid cash acquired company total net cash outflow foundation medicine transaction april group acquired controlling interest foundation medicine inc fmi treated fully consolidated subsidiary group since date common stock fmi publicly traded listed nasdaq stock code fmi december groups interest fmi june group entered merger agreement fmi acquire outstanding shares fmis common stock already owned group price usd per share cash merger agreement approved board roche special committee independent directors fmi full board directors tender offer launched july july transaction closed fmi became owned subsidiary group accounted full equity transaction cash consideration purchase public shares including shares issuable fmis outstanding stock incentive plans payment related fees expenses amounted usd billion set table amounts recorded equity change ownership interest subsidiaries foundation medicine transaction usd million chf million purchase publicly held shares settlement outstanding stock options vested restricted stock awards directly attributable transaction costs total cash consideration income tax effects change ownership interest subsidiaries roche finance report notes roche group consolidated financial statements roche group global restructuring plans group continued implementation various global restructuring plans initiated prior years global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs includes strategy plans diagnostics division includes pharmaceuticals divisions strategic realignment manufacturing network resourcing flexibility biologics manufacturing network includes plans outsourcing functions shared service centres external providers resourcing flexibility pharmaceuticals divisions commercial operations global product developmentstrategy organisations diagnostics division strategy plans diagnostics division incurred costs chf million mainly employeerelated matters chf million expenses process optimisation plans chf million chf million additional costs chf million included divestment subsidiary germany costs related reorganisation molecular diagnostics business chf million roche finance report roche group notes roche group consolidated financial statements site consolidation costs pharmaceuticals divisions strategic realignment manufacturing network chf million chf million mainly related exit manufacturing site clarecastle ireland expected costs environmental remediation clarecastle site reassessed resulted increase provisions chf million employeerelated costs chf million recorded redesign manufacturing south san francisco site costs resourcing flexibility plan biologics manufacturing network chf million chf million included closure manufacturing plant rio de janeiro brazil global restructuring plans initiatives pharmaceuticals division incurred costs chf million chf million mainly employeerelated major items chf million plans outsourcing functions shared service centres external providers chf million chf million chugai global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment reversal property plant equipment rightofuse assets accelerated depreciation property plant equipment rightofuse assets gains losses disposal property plant equipment rightofuse assets site closure costs total site closure costs divestment products businesses gains losses divestment subsidiaries gains losses divestment products businesses total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs roche finance report notes roche group consolidated financial statements roche group global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total royalties operating income pharmaceuticals diagnostics cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche finance report roche group notes roche group consolidated financial statements property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals divestment subsidiaries transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january reclassification rightofuse assets previously reported finance leases implementation ifrs leases january revised business combinations additions disposals divestment subsidiaries transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment charge roche finance report notes roche group consolidated financial statements roche group impairment charges property plant equipment mainly related idle plant global restructuring plans see note reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none december machinery equipment original cost chf billion chf billion net book value chf billion chf billion leased third parties see note capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling chf billion chf billion goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations divestment subsidiaries impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals roche pharmaceuticals product transactions chugai total pharmaceuticals division diabetes care centralised point care solutions molecular diagnostics tissue diagnostics sequencing divisional goodwill total diagnostics division roche finance report roche group notes roche group consolidated financial statements cashgenerating units used allocating goodwill pharmaceuticals division group made comprehensive reassessment cashgenerating units used allocating goodwill pharmaceuticals division conclusions reassessment follows within roche pharmaceuticals operating segment goodwill arises three broad types transactions strategic transactions transformative effect across whole division technology transactions acquired technologies range areas applications product transactions acquired products typically limited synergistic benefits outside immediate product therapeutic area cashgenerating unit goodwill arising strategic transactions roche pharmaceuticals operating segment cashgenerating unit goodwill arising technology transactions also roche pharmaceuticals operating segment however acquired technologies permanently cease operate treated disposal business cases goodwill deemed disposed fully impaired cashgenerating unit goodwill arising product transactions smallest identifiable group assets related revenues related costs arise development commercialisation products question synergistic benefits products therapeutic area revenues costs corresponding assets products also taken account acquired products permanently cease generate economic benefits treated disposal business cases goodwill deemed disposed fully impaired chugai separate operating segment groups financial reporting separate cashgenerating unit goodwill allocated group allocated goodwill roche pharmaceuticals operating segment listed basis allocation historical amounts goodwill arose individual transactions strategic transactions consist genentech foundation medicine flatiron health spark therapeutics technology transactions consist therapeutic human polyclonals dutalys santaris product transactions consist glycart tanox intermune diagnostics division divisions business areas sequencing business cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division goodwill arising viewics acquisition monitored divisional level recoverable amount used impairment testing based value use impairment charge charge chf million recorded diagnostics division partial writeoff goodwill related diabetes care business impairment result revised market assumptions related blood glucose monitoring area slower expected growth parts business roche finance report notes roche group consolidated financial statements roche group impairment charge pharmaceuticals division assessment potential impairment goodwill pharmaceuticals division carried using cashgenerating units set impairment charges totalling chf million recorded pharmaceuticals division intermune acquisition charge chf million recorded full writeoff goodwill intermune acquisition made main product acquired original transaction intermunes medicine idiopathic pulmonary fibrosis esbriet idiopathic pulmonary fibrosis progressive disease causes scarring lungs survival rate two three years diagnosis group recorded impairment charge chf million partial impairment esbriet product intangible use main factor leading decrease forecasted cash flows relative previous years longterm forecast due reduction sales expectations group reviewed assets liabilities acquired intermune transaction detail including initial valuations reports made purposes acquisition accounting subsequent integration process conclusion review apart intangible asset representing acquired rights esbriet related deferred taxation liabilities assets liabilities recorded groups balance sheet revenue streams parts acquired company synergistic benefits continued operations roche group group made required assessment potential impairment goodwill arose intermune acquisition using cashgenerating unit identifiable group assets related revenues related costs arose development commercialisation esbriet part groups regular process value use intangible asset representing acquired rights esbriet first tested impairment see note second step goodwill intermune acquisition tested impairment conclusion impairment tests substance remaining value group intermune acquisition estimated chf million solely relates acquired rights esbriet reported groups balance sheet product intangible asset use previously recorded impairment esbriet product intangible asset use therefore partially reversed income chf million recorded asset concerned written estimated recoverable value chf million main factor leading increase forecasted cash flows relative previous years longterm forecast due improvement sales expectations intangible asset continues amortised remaining estimated useful life three years see also note full impairment chf million recorded goodwill intermune acquisition revenues related costs arising development commercialisation esbriet fully utilised impairment testing process support value use esbriet product intangible asset use surplus esbriet revenues support carrying value goodwill neither synergistic benefits products therapeutic area accordingly separable recoverable value goodwill estimated zero fully impaired trophos acquisition charge chf million recorded full writeoff goodwill trophos acquisition made main product acquired original transaction trophos proprietary screening platformgenerated olesoxime tro developed spinal muscular atrophy sma rare debilitating genetic neuromuscular disease commonly diagnosed children group decided stop development compound therefore potential future revenues support carrying value goodwill neither synergistic benefits products franchise accordingly intangible assets relating product fully impaired see note goodwill deemed disposed also fully impaired diagnostics division charge chf million recorded centralised point care solutions business area full writeoff goodwill cmi acquisition made group decided change commercialisation strategy diagnostic instruments used haematology testing led full impairment product intangibles use acquired part cmi acquisition see note therefore goodwill deemed disposed also fully impaired roche finance report roche group notes roche group consolidated financial statements value use value use calculated using discounted expected cash flow approach posttax discount rate applied projected risk adjusted posttax cash flows terminal value discount rate groups weighted average cost capital cashgenerating units integrated operations across large parts group derived capital asset pricing model using data capital markets including government twentyyear bonds assessing value use cash flow projections based recent longterm forecasts approved management longterm forecasts include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation key assumptions used calculations period cash flow projections included longterm forecasts terminal value growth rate discount rate key assumptions used valueinuse calculations period terminal period terminal cash flow value discount rate cash flow value discount rate projections growth rate tax projections growth rate tax pharmaceuticals division years na years na diagnostics division years years cashgenerating units terminal value growth respective rate exceed longterm projected growth rate relevant market fair value less costs disposal goodwill arising chugai acquisition fair value less costs disposal determined reference publicly quoted price chugai shares sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai decreased publicly quoted share prices except diabetes care results sensitivity analyses demonstrated changes key assumptions would cause carrying values goodwill exceed recoverable amounts december key assumptions changes would result goodwill impairment chf million diabetes care december roche finance report notes roche group consolidated financial statements roche group intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations asset acquisitions additions disposals transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group roche finance report roche group notes roche group consolidated financial statements significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use rozlytrek ignyta acquisition roche pharmaceuticals years esbriet intermune acquisition roche pharmaceuticals years shionogi licence transaction roche pharmaceuticals years flatiron health acquisition roche pharmaceuticals years foundation medicine acquisition roche pharmaceuticals years kapa acquisition diagnostics years brahms licence transaction diagnostics years iquum acquisition diagnostics years product intangibles available use biontech licence transaction roche pharmaceuticals na dicerna licence transaction roche pharmaceuticals na forsight vision transaction roche pharmaceuticals na technology intangibles use adaptive licence transaction roche pharmaceuticals years classification intangible asset amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations asset acquisitions separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product roche finance report notes roche group consolidated financial statements roche group intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lowerthananticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling chf million recorded major items related charge chf million full impairment compound purchased separately driven change development plan asset concerned yet amortised fully written charge chf million following clinical data assessment two compounds assets concerned yet amortised fully written charge chf million due decision stop development compound alliance partner asset concerned yet amortised fully written charge chf million partial impairment compound developed together alliance partner mainly driven reduced revenue forecasts asset concerned yet amortised partially written charge chf million due decision stop development compound related collaboration activities alliance partner asset concerned yet amortised fully written charge chf million due decision stop development compound purchased separately asset concerned yet amortised fully written diagnostics division impairment charges totalling chf million recorded related charge chf million impairment molecular diagnostics product intangibles use acquired part geneweave acquisition main factors leading updated assumptions timelines research development expenses production costs asset concerned amortised fully written charge chf million impairment sequencing business product intangibles use acquired part ariosa acquisition mainly due change timelines launch related sequencing products asset concerned amortised fully written impairment charges pharmaceuticals division impairment charges totalling chf million net impairment reversals recorded related charge chf million due decision stop development five different compounds five different alliance partners assets concerned yet amortised fully written charge chf million due decision stop development compound purchased separately asset concerned yet amortised fully written charge chf million due decision stop development compound acquired part trophos acquisition asset concerned yet amortised fully written charge chf million partial impairment compound purchased separately due delayed timeline asset concerned yet amortised partially written charge chf million following clinical data assessment asset concerned yet amortised fully written charge chf million impairments assets concerned yet amortised fully written previously recorded impairment esbriet product intangible asset use partially reversed income chf million recorded asset concerned written estimated recoverable value chf million main factor leading increase forecasted cash flows relative previous years longterm forecast due improvement sales expectations intangible asset continues amortised remaining estimated useful life three years goodwill impairment charges related intermune acquisition discussed note roche finance report roche group notes roche group consolidated financial statements diagnostics division impairment charges totalling chf million recorded related charge chf million full impairment intangibles use available use related sequencing business mainly acquired part genia capp signature acquisitions factors leading impairment change commercialisation strategy related products change timelines future product development assets concerned partly amortised partly yet amortised fully written charge chf million partial impairment sequencing business product intangibles use acquired part ariosa acquisition factor leading impairment decrease forecasted cash flows following revised sales assumptions asset concerned amortised written estimated recoverable value chf million charge chf million full impairment centralised point care solutions product intangibles use acquired part cmi acquisition result decision change commercialisation strategy diagnostic instruments used haematology testing asset concerned amortised fully written potential commitments alliance collaborations purchase agreements within next three years group party inlicensing similar arrangements alliance partners intangible asset purchase agreements third parties including asset acquisitions arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments payments within next three years set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration purchase payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total roche finance report notes roche group consolidated financial statements roche group inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled chf billion chf billion inventory writedowns year resulted expense chf million chf million accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances withheld upon settlement total accounts receivable allowances doubtful accounts movements recognised allowance millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december allowances doubtful accounts january revised following implementation ifrs financial instruments bad debt expenses recorded marketing distribution costs totalled chf million expense chf million roche finance report roche group notes roche group consolidated financial statements marketable securities upon transition ifrs group elected restate comparative information result information provided ifrs basis information ias basis marketable securities millions chf ifrs ifrs ias equity securities availableforsale ias na na equity securities fair value profit loss ifrs na debt securities availableforsale ias na na debt securities fair value oci ifrs na money market instruments time accounts three months availableforsale ias na na money market instruments fair value oci ifrs na time accounts three months amortised costs ifrs na total marketable securities marketable securities held fund management purposes primarily denominated us dollars euros swiss francs money market instruments contracted mature within one year december debt securities contracted maturity millions chf ifrs ifrs ias within one year one five years five years total debt securities cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents roche finance report notes roche group consolidated financial statements roche group noncurrent assets upon transition ifrs group elected restate comparative information result information provided ifrs basis information ias basis noncurrent assets millions chf availableforsale investments held fair value ias na na availableforsale investments held cost ias na na equity investments fair value oci ifrs na equity investments fair value profit loss ifrs na loans receivable restricted cash receivables contracts customers receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets equity investments designated fair value oci mainly investments private companies pharmaceutical sector held part groups strategic alliance efforts equity investments classified availableforsale current assets current assets millions chf accrued interest income derivative financial instruments restricted cash cash collateral receivables receivables contracts customers receivables total financial current assets prepaid expenses accrued income taxes recoverable assets total nonfinancial current assets total current assets roche finance report roche group notes roche group consolidated financial statements accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable noncurrent liabilities noncurrent liabilities millions chf deferred income lease liabilities longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits following implementation ifrs leases see note noncurrent lease liabilities chf million recorded mainly leases formerly classified operating leases group lessee effective january current liabilities current liabilities millions chf deferred income lease liabilities accrued payroll related items interest payable derivative financial instruments cash collateral payables accrued chargebacks allowances separately payable accrued royalties commissions accrued liabilities total current liabilities december accrued liabilities included chf million shortterm genentech property purchase option exercise obligation paid june following implementation ifrs leases see note current lease liabilities chf million recorded mainly leases formerly classified operating leases group lessee effective january roche finance report notes roche group consolidated financial statements roche group provisions contingent liabilities provisions movements recognised liabilities millions chf contingent legal environmental restructuring consideration provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions divestment subsidiaries currency translation effects december current noncurrent december year ended december january reclassification lease liabilities implementation ifrs leases january revised additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration asset acquisitions divestment subsidiaries currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december following implementation ifrs leases see note provisions chf million relating onerous lease contracts reclassified lease liabilities effective january roche finance report roche group notes roche group consolidated financial statements chf million provisions utilised chf million chf million chf million included cash flows operating activities chf million chf million included cash flows business combinations payments made deferred contingent consideration arrangements see note legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict part regular review litigation matters management reassessed provisions recorded certain litigation matters based development various litigations notably avastinlucentis investigations meso case net increase provisions chf million major element expenses legal cases chf million net expense chf million details major legal cases outstanding disclosed environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey divested september estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago estimated remediation costs manufacturing site clarecastle ireland expected costs environmental remediation clarecastle site matters reassessed accordingly environmental provisions increased chf million net net environmental expenses chf million net expense chf million groups procedures environmental protection included annual report pages include actions taken group regard climate change notably groups commitment reduce greenhouse gas emissions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate strategic realignment manufacturing network resourcing flexibility plans diagnostics division significant provisions associated programmes address longterm strategy corporate relate plans outsourcing functions shared service centres external providers details given note contingent consideration provisions group party certain contingent consideration arrangements arising business combinations significant provisions discounted using average discount rate time value money material additional details measurement main movements provisions total potential payments arrangements provided note roche finance report notes roche group consolidated financial statements roche group provisions provisions relate items shown table exception employee provisions timing cash outflows nature uncertain provisions millions chf sales returns employee provisions items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note legal cases december provisions legal cases chf million chf million mainly related legal cases pharmaceuticals division chf million chf million diagnostics division chf million chf million provisions recorded cases settled mainly relating pharmaceuticals legal matters meso diagnostics legal case listed accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation mdl us district court middle district florida tampa division august mdl closed pendency mdl district court granted summary judgment favour hlr federal ibd cases proceeded affirmed us court appeals eleventh circuit actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county february superior court new jersey law division atlantic county held eightday evidentiary hearing whether plaintiffs experts testify accutane causes crohns disease february superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing prejudice agreedupon list crohns disease cases subject superior courts february order july new jersey appellate division reversed order excluding plaintiffs experts testifying accutane causes crohns disease reinstated dismissed cases finding trial court wrongfully barred plaintiffs expert witnesses hlr filed petition review new jersey supreme court granted december august supreme court issued decision whether plaintiffs experts testify accutane causes crohns disease supreme court reversed judgment new jersey appellate division concluded trial court properly excluded experts thereby dismissing cases alleging accutane caused plaintiffs crohns disease plaintiffs appeal crohns disease cases permanently dismissed roche finance report roche group notes roche group consolidated financial statements may superior court entered order granting summary judgment dismissing cases filed new jersey residents basis drug label adequate matter law since july superior court granted hlrs motion summary judgment adequacy label post ingestion cases jurisdictions superior court applied new jersey law jurisdictions granted hlrs motion dismissing approximately cases alternative superior court applied home state law granted summary judgment jurisdictions denied jurisdictions would resulted cases dismissed july new jersey appellate division affirmed dismissal cases reinstated judgments cases based strength hlrs warnings hlr dismissed plaintiffs filed petitions review new jersey supreme court granted december october supreme court issued decision cases reversed judgment new jersey appellate division reinstated cases basis drug label adequate matter law since plaintiffs appeal cases permanently dismissed january october superior court entered orders granting summary judgment dismissing cases failure prove accutane proximately caused ulcerative colitis plaintiffs appealed decisions february march superior court held evidentiary hearing whether plaintiffs experts testify accutane causes ulcerative colitis april superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing ulcerative colitis cases subject superior courts april order plaintiffs appealed decisions december hlr defending pending actions approximately cases appeal hearing january january new jersey appellate division issued decision whether plaintiffs experts testify accutane causes ulcerative colitis court affirmed trial courts ruling concluded trial court properly excluded experts thereby dismissing cases alleging accutane caused plaintiffs ulcerative colitis plaintiffs february seek review new jersey supreme court cases survive appeals additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche appealed verdict tar consiglio di stato july roche paid eur million fine protest avoid additional penalty fees recorded expense within general administration january european court justice rendered decision five questions referred european court justice consiglio di stato july consiglio di stato issued final verdict case upheld verdicts agcm tar respect fine agcm matter concluded italian ministry health italian regions notified group intention seek damages related matter january french competition authority fca issued statement objections roche genentech novartis regarding anticompetitive practices concerning commercialisation avastin lucentis france fca alleges roche genentech novartis abused collective dominant position french market treatment wet agerelated macular degeneration group vigorously defending matters addition group challenging policies regulations allowing offlabelunlicensed use reimbursement economic reasons various countries outcome matters determined time pdl inhibitor litigation july bristolmyers squibb co bms filed lawsuit genentech inc genentech delaware bms alleges genentechs sale tecentriq infringes us patent bms seeking judgment favour finding wilfulness monetary damages october genentech filed answer counterclaims seeking declaratory judgment invalidity patent may bms genentech agreed drop lawsuit without prejudice case refiled later date outcome matter determined time roche finance report notes roche group consolidated financial statements roche group average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending trial date set outcome matter determined time boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us one dismissed case canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time meso litigation february roche diagnostics corporation roche filed lawsuit us district court district delaware meso scale diagnostics llc meso patent infringement case involving certain us patents owned bioveris corporation bioveris company acquired group meso holds limited exclusive licence use certain aspects electrochemiluminescence ecl detection technology roche meso disagree scope licence lawsuit seeking declaratory judgment get judicial clarification roche infringing mesos licence november jury found roches use patents infringed scope mesos licence injunction granted jury awarded meso usd million damages meso expected claim additional prejudgment interest reimbursement attorneys fees future royalties group currently evaluating decision legal options addition pharmaceuticals legal cases listed currently provisions recorded potential future obligations confirmed occurrence nonoccurrence uncertain future events obligation measured sufficient reliability hemlibra litigation may baxalta inc baxalta gmbh together baxalta subsidiaries takeda pharmaceutical company limited filed patent infringement declaratory judgment patent infringement suit us district court district delaware alleging genentech chugai pharmaceutical co ltd chugai currently imminently would manufacture use sell offer sale import us hemlibra would infringe baxaltas us patent baxalta seeking judgment infringement injunctive monetary relief attorneys fees costs expenses may genentech served complaint genentechs response counterclaims complaint filed june june chugai waived service september chugai filed motion dismiss complaint lack personal jurisdiction december baxalta filed request preliminary injunction genentech inhibitor patients would subject injunction hearing held us district court district delaware june hearing baxalta withdrew request preliminary injunction inhibitor patients june baxalta submitted new proposed preliminary injunction order genentech would permitted sell hemlibra inhibitor patients noninhibitor patients currently hemlibra whether clinical trials selected noninhibitor patients additional medically diagnosed condition rendered factor viii therapies impracticable august us district court ruled baxalta denying request injunction september chugai dismissed case february us district court issued final judgment favour genentech stating hemlibra infringe baxaltas patent based courts definition key terms related patent february baxalta appealed decision group vigorously defending matter outcome matter determined time march case brought baxalta chugai japan tokyo district court ruled favour chugai notably hemlibra infringe baxaltas patent may baxalta appealed decision october japanese intellectual property high court issued ruling upholding tokyo district courts decision baxalta filed appeal japanese supreme court group vigorously defending matter outcome matter determined time roche finance report roche group notes roche group consolidated financial statements securities litigation june class action filed us district court district new jersey roche holding ltd two current officers lawsuit brings claims federal securities laws connection groups public disclosures particular respect matters relating two roches drugs herceptin perjeta september district court dismissed case concluding nothing misleading public disclosures subsequently plaintiffs filed second third amended complaint june us district court granted groups motion dismiss third amended complaint concluding nothing misleading public disclosures matter concluded iraqi ministry health october f hoffmannla roche ltd fhlr hoffmannla roche inc hlr genentech certain pharmaceutical andor medical device companies named defendants complaint filed federal district court district columbia us behalf us servicemembers relatives allege killed injured iraq iraq lawsuit complaint alleges defendants violated us antiterrorism act various state laws providing funding terrorist organisations sales practices pursuant pharmaceutical andor medical device contracts iraqi ministry health addition fhlr received inquiry july us department justice connection anticorruption investigation relating activities iraq including interactions iraqi government certain matters alleged iraq lawsuit october us department justice closed inquiry fhlr group vigorously defending matter outcome matter determined time arbitration regarding actemraroactemra chugai may medical research council lifearc formerly medical research council technology requested arbitration chugai pharmaceutical co ltd chugai arbitrator appointed august april united kingdom research innovation ukri established became successor title medical research council current claimants arbitration lifearc ukri collectively claimants sums sought chugai alleged breach obligations collaboration agreement dated august connection development humanised antihuman il receptor monoclonal antibody actemraroactemra claimed chugai obliged pay royalties claimants pursuant collaboration agreement january chugai executed formal settlement agreement claimants end arbitration settlement agreement chugai make lumpsum payment claimants sole settlement payment terms conditions settlement agreement including amount settlement payment confidential matter concluded roche finance report notes roche group consolidated financial statements roche group debt debt movements carrying value recognised liabilities millions chf january reclassification lease liabilities implementation ifrs leases na january revised proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt changes financing cash flows net gains losses redemption repurchase bonds notes amortisation debt discount financing costs business combinations net foreign currency transaction gains losses currency translation effects changes foreign exchange rates changes fair values hedging instruments changes december bonds notes commercial paper amounts due banks financial institutions finance lease obligations na borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche finance report roche group notes roche group consolidated financial statements bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollar notes fixed rate notes due september principal usd billion isin usba notes due september principal usd billion outstanding usd billion isin usbb notes due january principal usd billion isin usbm notes due september principal usd billion outstanding usd billion isin usbn na notes due september principal usd billion outstanding usd billion isin usbe na notes due november principal usd billion outstanding usd billion isin usbj na notes due may principal usd billion isin usbk na notes due january principal usd billion isin usbl na notes due september principal usd billion isin usbp na notes due march principal usd billion outstanding usd billion isin usuan usau notes due november principal usd billion isin usbh na us dollar notes floating rate notes due september principal usd billion isin usaz na euro medium term note programme fixed rate notes due june principal eur billion isin xs na notes due march principal usd billion isin xs notes due march principal eur billion outstanding eur billion isin xs notes due february principal eur billion isin xs na notes due august principal gbp billion outstanding gbp billion isin xs na notes due february principal eur billion isin xs na swiss franc bonds fixed rate bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch na genentech senior notes senior notes due july principal usd billion outstanding usd billion isin usac na total bonds notes roche finance report notes roche group consolidated financial statements roche group bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes group issue bonds notes issuance bonds notes september group completed offering chf billion chf billion fixed rate bonds coupon respectively bonds mature september september respectively bonds listed six swiss exchange group received chf million aggregate net proceeds issuance sale fixed rate bonds september group completed offering usd billion usd billion fixed rate notes coupon respectively notes mature september september respectively group received chf million aggregate net proceeds issuance sale fixed rate notes redemption repurchase bonds notes redemption us dollar notes due date september group repaid fixed rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes due date september group repaid floating rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes december group resolved exercise option call early redemption fixed rate notes principal amount usd billion par three months scheduled due date march cash outflow chf million plus accrued interest effective interest rate notes roche finance report roche group notes roche group consolidated financial statements december group completed tender offer redeem following instruments usd million fixed rate notes due september effective interest rate usd million fixed rate notes due september effective interest rate usd million fixed rate notes due september effective interest rate usd million fixed rate notes due november effective interest rate usd million fixed rate notes due july effective interest rate usd million fixed rate notes due march effective interest rate cash outflow chf million plus accrued interest loss redemption chf million included chf million paid bank fees redemption repurchase bonds notes redemption euro notes due date june group repaid fixed rate notes principal amount eur billion cash outflow chf million plus accrued interest effective interest rate bonds redemption swiss franc bonds due date september group repaid fixed rate bonds principal amount chf billion cash outflow chf million plus accrued interest effective interest rate bonds due date september group repaid bonds zero coupon principal amount chf billion cash outflow chf million plus accrued interest effective interest rate bonds cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf us dollar notes swiss franc bonds total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf euro medium term note programme euro notes euro medium term note programme us dollar notes us dollar notes swiss franc bonds total cash outflows redemption repurchase bonds notes roche finance report notes roche group consolidated financial statements roche group commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue usd billion unsecured commercial paper notes guaranteed roche holding ltd committed credit line available backstop supporting commercial paper program usd billion december july previously existing committed credit lines refinanced one new committed credit line initial maturity five years maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount usd billion average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies average interest rate december amounts outstanding chf million chf million due within one year roche finance report roche group notes roche group consolidated financial statements equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january revised net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b cost hedging reserve related eurusd crosscurrency swap included hedging reserve amounted chf million net tax equity january revised following implementation ifrs financial instruments roche finance report notes roche group consolidated financial statements roche group changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january implementation ifrs leases january revised net income recognised income statement financial assets fair value oci fair value gains losses equity investments fair value oci fair value gains losses taken retained earnings disposal equity investments fair value oci fair value gains losses debt securities fair value oci fair value gains losses transferred income statement debt securities fair value oci income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests december b entire amount transferred income statement reported financial income expense b cost hedging reserve related eurusd crosscurrency swap included hedging reserve amounted chf million net tax disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning equity attributable roche shareholders december restated roche finance report roche group notes roche group consolidated financial statements genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced chf billion chf billion allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value chf preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares december shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition duration pool extended indefinite period shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis holding ag basel owns participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security approved would result total distribution shareholders chf million subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities total equity instruments recorded within equity original purchase cost december fair value shares chf million fair value nonvoting equity securities chf billion equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note roche finance report notes roche group consolidated financial statements roche group reserves fair value reserve december fair value reserve represents cumulative net change fair value financial assets fair value oci asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs subsidiaries chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse january chugai announced split common stock effective july number issued shares increase threeforone split chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roche finance report roche group notes roche group consolidated financial statements roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement chugai shall offer roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnologybased drug discovery roche finance report notes roche group consolidated financial statements roche group foundation medicine april group acquired controlling interest foundation medicine inc fmi publicly owned us company based cambridge massachusetts entered investor rights agreement research development collaboration agreement several commercial collaboration agreements fmi treated fully consolidated subsidiary group since date december groups interest fmi common stock fmi publicly traded listed nasdaq stock code fmi fmi prepared financial statements accordance us gaap filed quarterly basis sec due certain consolidation entries differences fmis standalone us gaap results results fmi consolidated roche group accordance ifrs june group entered merger agreement fmi acquire outstanding shares fmis common stock already owned group price usd per share cash tender offer launched july july transaction closed fmi became owned subsidiary group accounted full equity transaction see note dividends dividends distributed third parties holding fmi shares divestment subsidiaries divestment subsidiaries november group sold wholly owned subsidiary roche diagnostics solutions gmbh berlin germany third party total consideration eur million deferred consideration become due november total loss divestment chf million reported global restructuring costs diagnostics operating segment included general administration group received deferred consideration eur million eur million respectively sale former subsidiary segrate site italy third party cash flow divestment subsidiaries millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration received deferred consideration received cash divested company total net cash inflow roche finance report roche group notes roche group consolidated financial statements noncontrolling interests changes equity attributable noncontrolling interests millions chf january implementation ifrs leases january revised net income recognised income statement chugai noncontrolling interests total net income recognised income statement equity investments fair value oci debt securities fair value oci cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income business combinations dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes ownership interest subsidiaries changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests roche finance report notes roche group consolidated financial statements roche group employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans chf million chf million assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plan us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation roche finance report roche group notes roche group consolidated financial statements pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contribution based certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility following plan change employee profitsharing plan mitarbeitergewinnbeteiligung longer qualifies defined contribution plan defined benefit plan resulted additions plan assets defined benefit obligation approximately chf billion operating income chf million recorded past service cost plan change switzerland amount chf million recorded pharmaceuticals division chf million diagnostics division chf million corporate past service income recorded within general administration pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans underfunding would normally remedied additional company contributions payments made group usd million payments comparative period included accelerated contributions benefit higher tax deduction pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contribution based minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai made additional voluntary contributions jpy billion pension plans none chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan postemployment benefit opeb plans represent approximately groups defined benefit obligation consist postemployment healthcare life insurance schemes mainly us plans mainly unfunded andor contributory employees group reimbursing retired employees directly financial resources groups major opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans payments usd million december ifrs funding status including reimbursement rights funded opeb plans us defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement roche finance report notes roche group consolidated financial statements roche group funding status funding groups various defined benefit plans responsibility respective senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level unfunded plans mainly groups german affiliates fully reserved pension obligations used selffinancing local affiliates operations ifrs funding status funded defined benefit plans decreased reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities plan assets responsibility investment strategies funded plans respective senior governance body board trustees assetliability studies performed regularly major pension plans studies examine obligations post employment benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets gain chf million loss chf million excludes actual return reimbursement rights recognition plan assets limited present value economic benefits available refunds plans reductions future contributions plans roche finance report roche group notes roche group consolidated financial statements defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january additions interest income plan assets reimbursement rights remeasurements plan assets reimbursement rights currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property primarily private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value chf million chf million debt instruments issued group fair value chf million chf million defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contribution based plan minimum guarantee result proportion defined benefit obligation relates closed plans expected decrease future defined benefit pension plans switzerland final benefit contribution based minimum guarantee remain open new employees roche finance report notes roche group consolidated financial statements roche group defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january additions current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour average life expectancy assumed individual age follows roche finance report roche group notes roche group consolidated financial statements defined benefit plans average life expectancy age major schemes years male female country mortality table switzerland bvg projected cmi model united states rp projected mp germany heubeck tables g projected cmi model mortality assumptions used pension plans switzerland based bvg applying continuous mortality investigation cmi model longterm rate used longevity improvements group used mortality assumptions pension plans germany heubeck tables g applying cmi model longterm rate longevity improvements financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases taking account expected inflation rates amongst factors expected rates pension increases generally linked expected inflation rate funding status plan expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf increase decrease defined benefit obligation life expectancy year increase discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year roche finance report notes roche group consolidated financial statements roche group cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional voluntary contributions related chugai benefit plans benefits paid unfunded plans estimated approximately chf million mostly relate german defined benefit plans equity compensation plans group operates several equity compensation plans including separate plans chugai ifrs sharebased payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai foundation medicine plans total operating expenses equitysettled cashsettled roche finance report roche group notes roche group consolidated financial statements cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai foundation medicine plans exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive nonvoting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period starting rights nontradable equitysettled awards tenyear duration vest phased basis four years rights granted sevenyear duration vest phased basis three years roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities rsus vest phased basis four years subject performance conditions rsus granted vest threeyearperiod currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period starting roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche finance report notes roche group consolidated financial statements roche group roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche performance share plan group offered future share nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards programme remain two annual threeyear cycles roche performance share plan psp includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number shares nonvoting equity securities individual award granted amount shares non voting equity securities allocated depends upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award granted result zero two shares nonvoting equity securities value adjustment depending upon achievement performance targets new psp awards granted roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years allocated recipients feb feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equitysettled awards tenyear duration vest phased basis four years options granted sevenyear duration vest phased basis three years roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche finance report roche group notes roche group consolidated financial statements roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche roche stocksettled stock restricted roche appreciation rights stock unit plan option plan progressively progressively progressively vesting period years years years contractual life years na years number granted year thousands weighted average fair value chf model used binomial market price binomial inputs option pricing model share price grant date chf exercise price chf expected volatility b na expected dividend yield na early exercise factor c na expected exit rate na fair value roche rsus equivalent share price date grant b volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream c early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour roche finance report notes roche group consolidated financial statements roche group leases implementation ifrs leases effective january group implemented ifrs leases ifrs replaces existing leases guidance including ias leases sets principles recognition measurement leases new standard resulted increased volume disclosure information annual financial statements main effect group lessee ifrs introduces single onbalance sheet lease accounting model requires lessee recognise assets liabilities leases lease liability reflects present value remaining lease payments rightofuse asset corresponds lease liability adjusted payments made lease commencement date lease incentives items related lease agreement result rightofuse assets totalling chf million lease liabilities totalling chf million recorded balance sheet effective january transition impacts balance sheet shown table transition impact ifrs roche group consolidated balance sheet selected items millions chf originally published application revised december ifrs january property plant equipment rightofuse assets current assets longterm debt noncurrent provisions noncurrent liabilities shortterm debt current provisions current liabilities total net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity weighted average incremental borrowing rate applied lease liabilities recognised transition operating lease commitments finance lease liabilities reported annual financial statements applying previous leasing standard ias reconciled lease liabilities recognised transition ifrs shown table reconciliation lease liabilities recognised transition january millions chf operating lease commitments undiscounted reported december applying ias finance lease liabilities reported december applying ias recognition exemption shortterm leases leases lowvalue assets lease arrangements commencement date december discounting lease liabilities recognised transition january applying ifrs thereof noncurrent liabilities current liabilities total roche finance report roche group notes roche group consolidated financial statements application new standard resulted part previously reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group currently expect effect material amount chf million main impact new standard statement cash flows cash flows respect leases previously reported operating leases reported part cash flows financing activities january previously included within cash flows operating activities impact new standard operating segment information given note key judgements made calculating initial application impact new standard include assessing whether arrangements contain lease determining lease term determining lease term extension termination options considered along facts circumstances may create economic incentive exercise extension option exercise termination option estimates include calculating discount rate based incremental borrowing rate group lessor application new standard material effects transition approach use practical expedients group applied cumulative catchup method transition cumulative effect adopting ifrs recognised adjustment opening balance retained earnings january restatement comparative information rightofuse assets generally measured amount equal lease liability adjusted payments made lease commencement date lease incentives items related lease agreement recognised balance sheet immediately date initial application rightofuse assets measured carrying amount ifrs applied since lease commencement date discounted using groups incremental borrowing rate january practical expedients permitted standard used notably reassess upon transition whether existing contract contains lease definition lease ifrs applied contracts entered changed january recognition exemptions shortterm leases leases lowvalue assets motor vehicles separate nonlease components instead account lease nonlease components single lease component apply ias onerous leases instead performing impairment review presentational changes result implementing ifrs group made number presentational changes notably present rightofuse assets separate line item balance sheet include lease liabilities current noncurrent liabilities group lessee group enters leasing transaction lessee mainly reasons convenience flexibility group good cash generation ability enjoys strong longterm investment grade credit ratings therefore typically enter leasing arrangements financing considerations main areas leases group entered property offices apartments small number leases represent value cars mostly sales representatives office equipment photocopiers similar roche finance report notes roche group consolidated financial statements roche group rightofuse assets reported groups leases shown table rightofuse assets movements carrying value assets millions chf buildings land machinery land improvements equipment total year ended december january cumulative catchup previously reported operating leases implementation ifrs reclassification property plant equipment previously reported finance leases implementation ifrs january revised business combinations additions disposals depreciation charge impairment reversal currency translation effects december cost accumulated depreciation impairment net book value impairment charges recorded rightofuse assets income chf million recognised within general administration related impairment reversal rightofuse assets lease arrangement assessed onerous contract liabilities reported groups leases shown table leases movements carrying value recognised liabilities millions chf january cumulative catchup previously reported operating leases implementation ifrs reclassification debt previously reported finance lease obligations implementation ifrs january revised increase new lease arrangements repayment lease liabilities business combinations disposals interest expense lease liabilities currency translation effects december noncurrent lease liabilities current lease liabilities total lease liabilities maturity analysis lease liabilities given note liquidity risk section shortterm leases leases lowvalue assets accounted using recognition exemption permitted ifrs expenses shortterm leases recognised straightline basis mainly include shortterm property leases employee apartments amount reported chf million expenses leases lowvalue assets recognised straightline basis mainly include certain office equipment amount reported chf million roche finance report roche group notes roche group consolidated financial statements expenses variable lease payments included measurement lease liabilities chf million income subleasing rightofuse assets chf million group enter sale leaseback transactions major cash flows respect leases group lessee shown table leases cash flows millions chf included cash flows operating activities included cash flows financing activities total lease payments cash flows operating activities include cash flows shortterm lease leases lowvalue assets variable lease payments cash flows financing activities include payment interest principal portion lease liabilities well prepayments made lease commencement date leases committed yet commenced may flatiron health inc entered binding lease agreement third party lease additional office space new york city us according agreement leased space made available different points time lease term february initial rightofuse asset lease liability related agreement estimated approximately usd million based current assumptions july foundation medicine inc fmi entered binding lease agreement third party lease laboratory office space building boston us constructed landlord location currently known boston seaport according agreement fmi committed lease building years commencement date lease currently expected initial rightofuse asset lease liability related agreement estimated approximately usd million based current assumptions group lessor diagnostics division group enters certain contracts include placement diagnostics instruments supply reagents consumables servicing arrangements depending upon term agreement instrument placement may result either finance lease operating lease group performs thorough customer assessment new leasing agreements signed usually group also retains rights terminate modify contracts certain conditions met finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease income finance leases recognised revenue amounts represent fair value instrument approximates present value minimum lease payments arrangement finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income following amounts recorded income respect finance leases finance leases selected items income millions chf selling profit difference sales cost sales finance income net investment lease currently group income variable lease payments finance leases carrying amount net investment finance leases reported receivables chf million chf million roche finance report notes roche group consolidated financial statements roche group finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one two years two three years three four years four five years five years total unearned finance income na na unguaranteed residual value na na net investment lease operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements income operating leases recognised revenue straightline basis lease term lease revenue entirely based variable lease payments subject subsequent reagent sales performance obligation reagents satisfied lease income chf million chf million included sales chf million chf million relates variable lease payments depending upon index rate leased assets reported within property plant equipment shown table machinery equipment subject operating leases movements carrying value assets millions chf leased use total january cost accumulated depreciation impairment net book value year ended december january reclassification rightofuse assets implementation ifrs leases january revised business combinations additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value roche finance report roche group notes roche group consolidated financial statements undiscounted amounts expected received noncancellable operating leases shown table operating leases future minimum lease receipts noncancellable leases millions chf within one year one two years two three years three four years four five years five years total minimum receipts earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions basic earnings per share nonvoting equity security chf diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf roche finance report notes roche group consolidated financial statements roche group statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics divisions calculated using indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment impairment reversal rightofuse assets operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns net gain loss disposal products adjustments cash generated operations disclosed note note group changed accounting policies leases following implementation ifrs leases effective january group applied cumulative catchup method transition meaning comparative statement cash flows year ended december restated main impact new standard statement cash flows cash flows respect leases group lessee previously reported operating leases reported part cash flows financing activities january previously included within cash flows operating activities cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total roche finance report roche group notes roche group consolidated financial statements cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing also included cash flows indicate groups transactions providers equity debt financing cash flows lease payments also included within financing activities following implementation ifrs leases see cash flows respect leases group lessee previously reported operating leases reported part cash flows financing activities effective january cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai noncontrolling interests dividend withholding tax total liabilities arising financing activities movements carrying value recognised assets liabilities millions chf cash principal derivative collateral portion financial receivables interest lease instruments payables debt payable liabilities net net total year ended december january cash flows outflow inflow noncash changes financing costs business combinations fair value foreign exchange rates december year ended december january implementation ifrs leases january revised cash flows outflow inflow noncash changes financing costs business combinations fair value foreign exchange rates december significant noncash transactions significant noncash transactions none except leasing transactions group lessee see note roche finance report notes roche group consolidated financial statements roche group risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part longterm forecasting controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits types authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets group considers financial asset default counterparty unlikely pay obligations group full assessing whether counterparty default group considers qualitative quantitative indicators eg overdue status based data developed internally certain financial assets also obtained external sources major part groups receivables past due days relate public customers risk default public customers considered low group reasonable supportable information demonstrate lagging default criterion appropriate particular customer segment accounts receivable december group trade receivables chf billion chf billion subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts group uses allowance matrix estimate allowance doubtful accounts trade receivables expected credit loss ecl rate based groups historical experience groups expectation economic conditions period receivables expected paid roche finance report roche group notes roche group consolidated financial statements customer credit risk exposure based accounts receivable days overdue ifrs millions chf overdue overdue overdue credit total current months months year impaired december gross carrying amount groups expected credit loss rate allowance doubtful accounts december gross carrying amount groups expected credit loss rate allowance doubtful accounts december groups combined trade receivables balance three us national wholesale distributors mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral considered measure expected credit losses trade receivables none since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables chf billion chf billion public private customers countries group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue net allowances doubtful accounts allowances nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total cash marketable securities excluding equity securities december group cash marketable securities excluding equity securities chf billion chf billion subject policy restricting exposures high quality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly cash cash equivalents held banks financial institutions predominantly rated investment grade respectively based moodys standard poors ratings cash shortterm time deposits subject rules limit groups exposure individual financial institutions impairment cash cash equivalents measured month expected credit losses ecl basis reference external credit ratings counterparties reflect short maturities exposures group considers cash cash equivalents low credit risk based external credit ratings roche finance report notes roche group consolidated financial statements roche group investments marketable securities excluding equity securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity counterparties credit rating least baa moodys bbb standard poors credit risk counterparties external ratings investment grade nonrated closely monitored reviewed individual basis rating analysis cash marketable securities excluding equity securities market values millions chf fair value fair value oci amortised costs oci amortised costs total month ecl month ecl total month ecl month ecl aaa range aa range range bbb range total investment grade bbb range investment grade unrated total gross carrying amounts loss allowance loss allowance related fair value oci affect carrying amount marketable securities excluding equity securities booked corresponding oci reserve instead debt securities amortised cost fair value oci investment grade therefore considered low risk thus impairment allowance determined month expected credit losses ecl reference external credit ratings counterparties debt securities group observed significant increase credit risk would require application lifetime expected credit losses impairment model addition material movements loss allowance respectively master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses financial assets excluding equity investmentssecurities impairment losses impairment losses chf million liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit line various financial institutions totalling chf billion chf billion chf billion chf billion serve backstop line commercial paper program july previously existing committed credit lines refinanced one new committed credit line initial maturity five years roche finance report roche group notes roche group consolidated financial statements remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf carrying less value total year years years years december debt bonds notes debt contingent consideration accounts payable noncurrent liabilities lease liabilities current liabilities lease liabilities derivative financial instruments total financial liabilities december debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities derivative financial instruments total financial liabilities takeorpay commitments group entered contract manufacturing agreements various companies develop manufacturing capacity flexibility mainly pharmaceuticals division future minimum takeorpay commitments within agreements total potential commitment group chf billion december chf billion market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads roche finance report notes roche group consolidated financial statements roche group market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component decreased due repayment early redemption longterm debt second half well due reduction underlying interest rates across major currencies foreign exchange component increased due unfavourable exposure mix price component remained stable foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro groups foreign exchange risk management strategy preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously immunise unfavourable developments foreign exchange rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments shortterm debt groups interest rate risk management strategy optimise net interest result group may use forward contracts options interest rate swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events roche finance report roche group notes roche group consolidated financial statements capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholding chugai see note chugai public company objectives policies processes managing capital determined chugai management financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost liabilities value fair value december noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities total financial liabilities roche finance report notes roche group consolidated financial statements roche group carrying value fair value financial instruments millions chf financial instruments mandatorily financial financial fair value instruments fair value assets total profit fair value hedging amortised financial carrying loss oci instruments cost liabilities value fair value december noncurrent assets equity investments financial noncurrent assets accounts receivable marketable securities equity securities debt securities money market instruments time accounts three months cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable noncurrent liabilities current liabilities total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche finance report roche group notes roche group consolidated financial statements fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total december marketable securities equity securities fair value profit loss debt securities fair value oci money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value december marketable securities equity securities fair value profit loss debt securities fair value oci money market instruments fair value oci derivative financial instruments equity investments fair value oci equity investments fair value profit loss financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date equity investments fair value oci fair value profit loss based valuation model uses recently published observable market data group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none roche finance report notes roche group consolidated financial statements roche group level fair values details determination level fair value measurements set contingent consideration arrangements millions chf january arising business combinations utilised settlements total gains losses included income statement unused amounts reversed recorded within general administration additional amount created recorded within general administration discount unwind included financing costs total gains losses included comprehensive income currency translation effects december contingent consideration provisions decreased mainly due reversal provisions payment milestones payments chf million made milestones related dutalys santaris ariosa geneweave genia acquisitions chf million income net mainly reversal provisions related santaris ariosa geneweave acquisitions contingent consideration arrangements group party certain contingent consideration arrangements arising business combinations fair values determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rates higher riskadjusted discount rate lower december total potential payments contingent consideration arrangements could chf billion chf billion follows potential payments contingent consideration arrangements millions chf acquisition year acquired operating segment dutalys roche pharmaceuticals santaris roche pharmaceuticals geneweave diagnostics genia diagnostics ariosa diagnostics others various diagnostics december roche finance report roche group notes roche group consolidated financial statements derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount collateral arrangements movements cash collateral receivable accrued liability millions chf january net cash delivered group fair value currency translation effects december hedge accounting described groups risk management strategy hedge transaction exposures arising foreign currency flows monetary positions held foreign currencies well generate appropriate mix fixed floating rate exposures level hedging depends market conditions business requirements group group designates specific interest rate risk management objective ensure predetermined level interest rate risk exposure floating rate hedge effectiveness determined inception hedge relationship periodic prospective effectiveness assessments reporting date ensure economic relationship exists hedged item hedging instrument group performs qualitative assessment hedge effectiveness using critical terms match method critical terms hedged items hedging instruments match group concludes risks hedged hedged items hedging instruments sufficiently aligned inherent mismatch hedging relationship hedge ratio applies actual quantities hedged hedge accounting accounting treatment sources ineffectiveness prospective effectiveness assessment method risk category prospective effectiveness accounting treatment potential sources ineffectiveness assessment method interest rate foreign exchange rate fluctuations cash flow hedge counterparty credit risk critical terms match foreign exchange rate fluctuations cash flow hedge lower volume hedged items critical terms match counterparty credit risk interest rate fluctuations fair value hedge counterparty credit risk critical terms match roche finance report notes roche group consolidated financial statements roche group ineffective portion hedge accounting recognised income statement included financial income expense measured using hypothetical derivative method cash flow hedges cumulative dollar offset method fair value hedges december december respectively none potential sources ineffectiveness individually collectively resulted material amounts actual ineffectiveness reported hedge accounting relationships table shows fair values nominal amounts derivative financial instruments including range maturity nominal amount hedging instruments designated hedging instruments cash flow hedge fair value hedge december group following cash flow hedges fair value hedges designated qualifying hedge relationship fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps eur million fixed usd risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total fair values nominal amounts derivatives used hedge accounting december fair value asset fair value liability nominal amount million chf million chf maturity range cash flow hedges risk hedged interest rate foreign exchange rate fluctuations crosscurrency swaps eur million fixed usd risk hedged foreign exchange rate fluctuations forward exchange contracts jpy billion total fair value hedges risk hedged interest rate fluctuations interest rate swaps usd million interest rate swaps eur million interest rate swaps chf million total fair values derivative financial instruments used hedge accounting included current assets see note current liabilities see note groups approach managing market risk including interest rate risk foreign currency risk discussed market risk section note cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro december instruments recorded net fair value liability chf million net fair value liability chf million ineffective portion chugai entered forward exchange contracts hedge part foreign translation exposure swiss franc us dollar december instruments recorded fair value assets chf million fair value liabilities chf million fair value assets chf million fair value liabilities chf million ineffective portion roche finance report roche group notes roche group consolidated financial statements none hedging instruments currently held applying hedge accounting affected interbank offered rates ibor reform carrying amount items designated hedged items cash flow hedging relationship millions chf assets liabilities assets liabilities december bonds notes risk hedged crosscurrency swaps interest rate foreign exchange rate fluctuations bonds notes inventories risk hedged forward exchange contracts foreign exchange rate fluctuations inventories hedging reserve continuing hedging relationships millions chf cross forward cross forward currency exchange currency exchange total swaps contracts total swaps contracts january gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation effects december entire amount transferred income statement reported financial income expense hedging relationships hedge accounting longer applied none changes hedging reserve within equity shown note expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow roche finance report notes roche group consolidated financial statements roche group fair value hedges group entered interest rate swaps hedge exposure changes fair value fixedterm debt instruments respect benchmark interest rate december instruments recorded fair value assets chf million fair value assets chf million fair value liabilities chf million fair value adjustments chf million recorded interest rate swaps chf million interest rate swaps currently held applying hedge accounting referenced benchmark rate london interbank offered rate libor except hedging instrument hedging portion eur million notes due march fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments groups approach managing market risk including interest rate risk discussed market risk section note carrying amount items designated hedged items fair value hedging relationship millions chf fair value fair value adjustments adjustments liabilities cumulative current year december bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes december bonds notes risk hedged interest rate swaps interest rate fluctuations bonds notes december group resolved exercise option call early redemption fixed rate notes principal amount usd billion par three months scheduled due date march see note resulted termination fair value hedge accounting applied interest rate swaps nominal value usd million fair value less chf million date termination net investment hedges group net investment hedges related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares december shareholder group announced would continue shareholder pooling agreement modified shareholder composition group consists mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement existed since duration pool extended indefinite period figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling chf chf dr oeri received remuneration totalling chf chf transactions group individual members shareholder group exception dr jrg duschmal worked postdoc roche end september roche finance report roche group notes roche group consolidated financial statements subsidiaries associates listing group subsidiaries associates included note listing excludes chugais subsidiaries well material companies notably companies inactive dormant liquidation transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates key management personnel total remuneration key management personnel chf million chf million members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees chairman board directors members corporate executive committee cec roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members cec members cec also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members cec included table full calendar year joined cec similarly members cec retiring partway year included full calendar year left cec remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included remuneration report included annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel roche finance report notes roche group consolidated financial statements roche group reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year subject approval annual general meeting march issued march number awards fair value per award calculated grant date equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan contributions paid members corporate executive committee millions chf roche connect transactions former members board directors corporate executive committee pensions totalling chf million paid group former corporate executive committee members chf million defined benefit plans transactions group various defined benefit plans employees group described note roche finance report roche group notes roche group consolidated financial statements list subsidiaries associates following listing group subsidiaries associates excludes chugais subsidiaries well material companies notably companies inactive dormant liquidation listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich stock code share ro valor stock code genussschein rog valor isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million nonlisted companies share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ars roche diabetes care argentina sa tigre ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited north ryde aud roche products pty limited dee aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk usd belgium nv roche sa brussels eur roche diagnostics belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche products limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad syntex pharmaceuticals international limited hamilton usd bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche shanghai pharmaceuticals consulting co ltd shanghai cny roche shanghai pharmaceuticals trading co ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai ltd shanghai usd roche diagnostics suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions colombia productos roche sa bogot cop costa rica roche services americas sociedad de responsabilidad limitada san jose crc roche servicios sa heredia usd cte d'ivoire roche cte d'ivoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer og kemikalier hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche diagnostics egypt trading sae giza egp roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp el salvador productos roche el salvador sa de cv antiguo cuscatlan svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur timkl sas montbonnotsaintmartin eur trophos sa marseille eur georgia roche georgia llc tbilisi gel germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur fmi germany gmbh penzberg eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostics automation solutions gmbh waiblingen eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche privacy gmbh grenzachwyhlen eur roche real estate services mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur signature diagnostics gmbh potsdam eur ghana roche products ghana limited accra ghs greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sociedad annima guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostics india private limited mumbai inr roche products india private limited mumbai inr viewics india private limited pune inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur spark therapeutics ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd hod hasharon ils italy roche diabetes care italy spa monza eur roche diagnostics spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostics kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr roche services asia pacific sdn bhd kuala lumpur myr mauritius roche products mauritius ltd moka mur mexico productos roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn north macedonia roche makedonija dooel skopje eur norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr panama productos roche panama sa panama city pab productos roche interamericana sa prisa panama city usd peru productos roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation rochemoscow jsc moscow rub limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostics rus moscow rub saudi arabia roche diagnostics saudi arabia llc riyadh sar roche products saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystems pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche diagnostics proprietary limited midrand zar roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain roche diabetes care spain sl sant cugat del valls eur roche diagnostics sl sant cugat del valls eur roche farma sa madrid eur sweden roche ab solna sek roche diagnostics scandinavia ab solna sek roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmann la roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabetes care switzerland ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd basel chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim sirketi istanbul try roche diagnostics turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah united arab emirates roche diabetes care middle east fzco dubai aed roche diagnostics middle east fzco dubai aed roche pharmaceuticals middle east fzco dubai aed united kingdom intermune holdings limited welwyn garden city gbp roche diabetes care limited burgess hill gbp roche diagnostics limited burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp spark therapeutics uk limited london gbp tusk therapeutics limited welwyn garden city gbp united states adheron therapeutics inc south san francisco usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapolis usd flatiron health inc new york usd forsight vision inc south san francisco usd foundation medicine securities corporation cambridge usd foundation medicine inc cambridge usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd hoffmannla roche inc little falls usd surviving corp south san francisco usd igen international inc pleasanton usd igen ls llc pleasanton usd ignyta inc south san francisco usd intermune inc south san francisco usd iquum inc marlborough usd jecure therapeutics inc south san francisco usd kapa biosystems inc wilmington usd memory pharmaceuticals corp little falls usd mysugr inc encinitas usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions united states continued roche health solutions inc indianapolis usd roche holdings inc south san francisco usd roche laboratories inc little falls usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequencing solutions inc pleasanton usd roche tcrc inc little falls usd seragon pharmaceuticals inc south san francisco usd spark therapeutics inc philadelphia usd spark therapeutics international holdings inc philadelphia usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutic human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc santa clara usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef vietnam roche pharma vietnam company limited ho chi minh city vnd roche vietnam company limited ho chi minh city usd share capital less local currency units significant accounting policies consolidation policy subsidiaries companies group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt roche finance report notes roche group consolidated financial statements roche group foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income revenue sales revenue sale goods supplied product sales services rendered recoded sales sales recognised promise customer contract performance obligation satisfied transferring control promised goods services customer control promised good service refers ability direct use obtain substantially remaining benefits goods services control usually transferred upon shipment delivery upon receipt goods customer services rendered accordance delivery acceptance terms agreed customers goods subject installation instruments sold diagnostics division sales generally recognised upon completion installation customers site customer acceptance amount sales recognised transaction price based consideration group expects receive exchange goods services excluding amounts collected behalf third parties value added taxes taxes directly linked sales contract contains one performance obligation transaction price allocated performance obligation based relative standalone selling prices instruments diagnostics division may sold together goods reagents consumables well services single contract several contracts combined revenue recognition purposes sales recognised upon satisfaction performance obligations contract instruments either sold cash instalment sales transactions otherwise made available customers finance lease operating lease transactions finance leases arrangements group transfers substantially risks rewards ownership customer treated finance lease arrangements income finance leases recognised revenue amounts represent fair value instrument approximates present value minimum lease payments arrangement interest rates embedded finance lease arrangements approximately market rates income finance leases comparable revenue outright sales finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest rate method recorded royalty operating income operating leases income operating leases recognised revenue straightline basis lease term lease revenue entirely variable subject subsequent reagent sales performance obligation deliver reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices fair values requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise contracts distributors sales recognised goods physically transferred distributor consignment arrangement distributor acts agent cases sales recognised control goods transfers endcustomer distributors commissions presented within marketing distribution commissions similar payments distributors acting principals deducted sales unless payments exchange distinct service roche finance report roche group notes roche group consolidated financial statements consideration received group exchange goods services may fixed variable variable consideration recognised considered highly probable significant revenue reversal occur underlying uncertainty related variable consideration subsequently resolved common elements variable consideration pharmaceuticals division listed government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us contractual price reductions include rebates chargebacks result contractual agreements primarily volume based performance based cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted effect sales earnings period adjustment sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities provisions sales returns recorded balance sheet provisions group recognises deferred income contract liability consideration received become receivable group transfers promised goods services customer deferred income mainly relates remaining performance obligations goods free charge certain patient access similar programmes reagents consumables services remaining performance obligations partially unsatisfied longterm contracts either included deferred income related amounts group expects receive goods services yet transferred customers existing non cancellable otherwise enforceable contracts mainly associated contracts minimum purchase commitments related reagents consumables previously sold instruments well monitoring maintenance services contracts original duration one year less group elected practical expedient disclose transaction price remaining performance obligations end reporting period point time group expects recognise sales royalty operating income royalty operating income includes royalty income income outlicensing agreements income disposal products items royalty income earned licence recognised underlying sales recorded licensee income outlicensing agreements typically arises receipt upfront milestone similar payments third parties granting licence product technologyrelated intellectual property ip outlicensing agreements may entered obligation may include commitments conduct research latestage development regulatory approval comarketing manufacturing licences granted usually rights use ip generally unique therefore basis allocating revenue performance obligations makes use residual approach upfront payments licensing fees usually recognised upon granting licence unless income shall deferred performance obligations using residual approach deferred income released recognised revenue performance obligations satisfied milestone payments typically received upon reaching specific scientific milestone development milestone upon achieving certain annual sales milestone commercial milestone development milestone income recognised point time highly probable respective milestone event criteria achieved risk revenue reversal considered remote commercial milestone income accrued recognised revenue highly probable annual sales milestone reached period payments received disposal product similar rights recognised revenue upon transfer control rights extent payments relate performance obligations portion deferred using residual approach recognised revenue activities manufacturing services rendered income profitsharing arrangements collaboration partners recognised underlying sales cost sales recorded collaboration partners also included income services rendered usually part groups primary business activities extent revenue recorded sales recognised control transfers performance obligations satisfied roche finance report notes roche group consolidated financial statements roche group cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available roche finance report roche group notes roche group consolidated financial statements defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service cost charged appropriate income statement heading within operating results past service cost including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred roche finance report notes roche group consolidated financial statements roche group leases group lessee policy applicable january inception contract group assesses whether contract contains lease contract contains lease contract conveys right control use identified asset period time exchange consideration group recognises rightofuse asset corresponding lease liability contract contains lease lease commencement date except shortterm leases leases lowvalue assets payments shortterm leases leases lowvalue assets recognised expense straightline basis term respective lease lease liability initially measured present value future lease payments paid lease commencement date lease payments discounted using interest rate implicit lease readily determinable groups incremental borrowing rate respective markets lease payments include fixed payments variable payments depend index rate known lease commencement date payments exercising extension purchase options group reasonably certain exercise lease liability subsequently measured amortised costs using effective interest method remeasured corresponding adjustment related rightofuse asset change future lease payments following contract renegotiation change index rate reassessment options rightofuse asset initially measured cost comprises initial amount lease liability adjusted payments made lease commencement date includes initial direct costs incurred expected costs obligations dismantle remove refurbish underlying asset less incentives received rightofuse assets depreciated straightline basis lease commencement date shorter lease term useful life underlying asset rightofuse assets assessed impairment whenever indication impairment group lessee policy applicable january group classified leases substantially transferred risks rewards ownership finance leases finance leases capitalised property plant equipment start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method leases classified operating leases operating leases existed substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period lease group lessor certain assets mainly diagnostics instruments leased thirdparty customers finance operating lease arrangements transactions may entered separate contracts combined contracts including reagents consumables services treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred case lease finance lease operating lease arrangements take legal form lease nevertheless convey right use asset also covered assessments finance leases finance lease assets reported receivables amount equal net investment lease income finance leases recognised revenue amounts represent standalone selling price instrument approximates present value minimum lease payments arrangement minimum lease payments exclude variable lease payments contingent rent finance income finance lease arrangements longer twelve months deferred subsequently recognised based pattern approximates use effective interest method recorded royalty operating income operating leases income operating leases recognised revenue straightline basis lease term amounts represent standalone selling price instrument approximates present value minimum lease payments arrangement minimum lease payments exclude variable lease payments contingent rent lease revenue entirely based variable lease payments subject subsequent reagent sales recognised performance obligations reagents satisfied sales net discounts based estimates regarding related obligations including standalone selling prices requires judgement determine different obligations satisfied including whether enforceable purchase commitments obligations exist arise mergers acquisitions business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses roche finance report roche group notes roche group consolidated financial statements asset acquisitions asset acquisitions acquisitions legal entities qualify business combinations date acquisition group initially recognises individual identifiable assets acquired liabilities assumed cost group date acquisition allocated individual identifiable assets liabilities basis relative fair values date acquisition subsequent consideration performancerelated development milestones recognised intangible assets specific milestones achieved transactions give rise goodwill material directly attributable acquisition related costs included cost acquired assets goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value available use intangible assets amortised straight line basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment rightofuse assets intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs disposal value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciationamortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cash generating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process intermediates includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses roche finance report notes roche group consolidated financial statements roche group receivables including accounts receivable receivables carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances receivable represents right consideration unconditional excludes contract assets allowance doubtful accounts recorded expected credit losses term receivables estimates based specific indicators ageing customer balances specific credit circumstances groups historical loss rates category customers adjusted forwardlooking macroeconomic data expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience receivables written either partly full reasonable expectation recovery receivables written group continues engage enforcement activities attempt recover receivable due recoveries made recognised profit loss trade lease receivables group applies simplified approach prescribed ifrs requirespermits use lifetime expected loss provision initial recognition receivables group measures allowance doubtful accounts equal credit losses expected lifetime trade lease receivables cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available financial instruments policy applicable january january group classifies financial instruments following measurement categories disclosed note amortised cost fair value oci fair value oci equity investments fair value profit loss including hedging instruments classification depends groups business model managing financial assets contractual terms cash flows group reclassifies debt securities financial assets amortised cost business model managing assets changes initial recognition group measures financial asset fair value plus case financial asset fair value profit loss transaction costs directly attributable acquisition financial asset transaction costs financial assets carried fair value profit loss expensed profit loss roche finance report roche group notes roche group consolidated financial statements amortised cost assets held collection contractual cash flows cash flows represent solely payments principal interest measured amortised cost less provision impairment gain loss debt security subsequently measured amortised cost part hedging relationship recognised profit loss asset derecognised impaired interest income financial assets included financial income using effective interest rate method assets amortised cost mainly comprised accounts receivable cash cash equivalents time accounts three months fair value comprehensive income fair value oci financial assets held collection contractual cash flows selling financial assets assets cash flows represent solely payments principal interest initially recorded subsequently carried fair value changes fair value recorded comprehensive income except recognition impairment gains losses interest revenue foreign exchange gains losses recognised profit loss financial asset derecognised cumulative gain loss previously recognised oci reclassified equity profit loss interest income financial assets included financial income using effective interest rate method fair value comprehensive income assets mainly comprised money market instruments debt securities equity investments fair value comprehensive income fair value oci equity investments private biotechnology companies kept part groups strategic alliance efforts assets subsequently measured fair value dividends recognised financial income profit loss unless dividend clearly represents recovery part cost investment net gains losses recognised oci included fair value reserve asset derecognised cumulative gain loss previously recognised oci reclassified within equity fair value reserve retained earnings never profit loss fair value profit loss financial assets whose performance evaluated fair value basis gain loss financial asset subsequently measured fair value profit loss part hedging relationship recognised profit loss presented within financial income expense period arises fair value profit loss assets mainly comprised equity investmentssecurities contingent consideration liabilities initially recorded subsequently carried fair value changes fair value recorded general administration within operating results income statement fair value profit loss hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value less transaction costs subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire policy applicable january financial instruments previously classified availableforsale non derivative financial assets either designated classified financial asset category availablefor sale assets initially recorded subsequently carried fair value changes fair value recorded comprehensive income except impairments interest foreign exchange components investment derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets mainly comprised marketable securities roche finance report notes roche group consolidated financial statements roche group impairment financial assets group recognises loss allowances expected credit losses ecl financial assets measured amortised cost debt securities measured fair value oci trade lease receivables group measures allowance doubtful accounts amount equal lifetime ecl debt securities carried fair value oci debt securities financial assets amortised cost determined low credit risk based external credit ratings counterparties group measures loss allowances amount equal month ecl group considers debt securities low credit risk credit risk rating equivalent globally understood definition investment grade group considers least baa moodys bbb standard poors credit risk debt securities carried fair value oci debt securities financial assets amortised cost increased significantly since initial recognition group measures loss allowances amount equal lifetime ecl group assumes credit risk instruments increased significantly days past due financial assets written either partially full realistic prospect recovery generally case group determines customer assets sources income could generate sufficient cash flows repay amounts subject writeoff however financial assets written still subject enforcement activities order comply groups policy recovery amounts due hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions eligibility hedging hedged instruments formal designation documentation well hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense roche finance report roche group notes roche group consolidated financial statements taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future amount tax liabilities uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans changes accounting policies group adopted ifrs leases including consequential amendments standards effective january group applied cumulative catchup method transition meaning comparative results restated full details given note group also implemented various minor amendments existing standards interpretations including ifric uncertainty income tax treatments material impact groups overall results financial position future new revised standards group currently assessing potential impacts various new revised standards interpretations group yet applied based analysis standards interpretations mandatory january group anticipate material impact groups overall results financial position roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group statutory auditors report statutory auditors report general meeting roche holding ltd basel report audit consolidated financial statements opinion audited consolidated financial statements roche holding ltd subsidiaries group comprise consolidated balance sheet december consolidated income statement consolidated statement comprehensive income consolidated statement changes equity consolidated statement cash flows year ended notes consolidated financial statements including summary significant accounting policies opinion consolidated financial statements pages give true fair view consolidated financial position group december consolidated financial performance consolidated cash flows year ended accordance international financial reporting standards ifrs comply swiss law basis opinion conducted audit accordance swiss law international standards auditing isas swiss auditing standards responsibilities provisions standards described auditors responsibilities audit consolidated financial statements section report independent group accordance provisions swiss law requirements swiss audit profession well iesba code ethics professional accountants fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion key audit matters chargebacks rebates sales returns us pharmaceuticals business carrying value product intangible assets income tax uncertain tax positions key audit matters matters professional judgement significance audit consolidated financial statements current period matters addressed context audit consolidated financial statements whole forming opinion thereon provide separate opinion matters roche finance report statutory auditors report roche group chargebacks rebates sales returns us pharmaceuticals business key audit matter response groups pharmaceuticals business makes sales audit procedures included amongst others sample various customers us fall certain basis obtaining managements calculations accrued commercial governmentmandated contracts purchasing liabilities provisions accounts receivable deductions reimbursement arrangements testing accuracy calculations assessing significant medicaid b drug discount appropriateness key inputs assumptions used program group also provides right return estimates performing assessment referenced us customers certain products return periods internal external sources information including cases extend several years future terms applicable contracts us government pricing arrangements result deductions gross amounts invoiced information historical rates chargebacks rebates arriving revenue create obligations group historical rates sales returns consideration current provide customers credits chargebacks rebate trends payments estimated amounts deducted gross sales recorded accrued liabilities rebates also evaluated accuracy managements estimates provisions sales returns deduction accounts comparing rates used historical estimates rates receivable chargebacks estimates based actual rebate payments chargebacks assessed analyses existing contractual legislatively mandated changes accrual rates used within estimates obligations recent trends historical experience comparing accrual rates current chargeback rebate payment sales return trends management determined accrued liabilities deductions accounts receivable expected also evaluated appropriateness groups chargebacks rebates predominantly medicaid revenue recognition accounting policies including chf million necessary december recognition measurement deductions gross sales additionally provisions sales returns mainly relating relating chargebacks rebates sales returns products near loss exclusivity chf million related disclosures recorded december focused area arrangements complex establishing appropriate yearend position requires significant judgement estimation management assumptions required estimating provisions sales returns also made complicated given recent impending loss exclusivity us groups pharmaceutical products information chargebacks rebates sales returns us pharmaceuticals business refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note revenue note accounts receivable note current liabilities note provisions contingent liabilities roche finance report roche group statutory auditors report carrying value product intangible assets key audit matter response group significant product intangible assets audit procedures included amongst others challenging december chf million acquired robustness key assumptions used determine business combinations inlicensing arrangements recoverable amounts including forecast revenues useful comprise product intangibles use chf million lives discount rates challenge based amortised product intangibles available understanding commercial prospects individual use chf million amortised impairment products well relevant business areas markets assessment carried product intangibles operate used valuation specialists evidence asset may impaired assist us evaluating assumptions methodologies intangible assets yet available use also used management relation discount rates tested impairment annually assessed key inputs projected pricing volumes products projected share product intangibles use chf million predominantly therapeutic area vitro diagnostic market comparing relate acquired products launched relevant assumptions industry forecasts reviewing key risk ability successfully commercialise analyst commentaries retrospective assessment products concerned key estimates assumptions include accuracy previous projections compared revenue growth timing impact loss exclusivity managements assumptions external data discount rates development commercialisation available performed sensitivity analysis individual competing products drivers revenue growth include intangible asset impairment models assess level persistence rate treatment rate market share sensitivity key assumptions could focus work areas assess managements allowance risk product intangibles available use chf million mostly represent inprocess research development product intangibles yet available use audit assets due inherent uncertainties research included assessing reasonableness managements development processes intangible assets available assumptions regarding probability obtaining regulatory use particularly risk impairment impairment approval comparison industry practice past assessment requires management make key assumptions history consideration groups internal governance judgements clinical technical commercial approval processes also interviewed senior viability new products accordingly also focused research development commercial personnel order audit work areas risks include inability understand challenge assumptions achieve successful trial results obtain required clinical regulatory approvals highly competitive business environment therapeutic areas group significant assets research development information carrying value productrelated intangible assets refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note intangible assets roche finance report statutory auditors report roche group income tax uncertain tax positions key audit matter response group operates across wide range different tax audit procedures included amongst others obtaining jurisdictions around world thus tax treatments understanding uncertain tax positions inquiry tax filings subject challenge local tax authorities employees tax department management respect crossborder transfer pricing arrangements affiliates inspected documentation relation tax goods services financing transactionrelated tax exposure items including correspondence tax authorities matters connection integration investments reports issued tax advisors verify whether divestments licensing contracts tax treatments uncertain tax positions considered provided involving uncertainty include agreements transfer pricing necessary arrangements affiliates involved groups global manufacturing supply chains significant items challenged managements judgement regarding eventual resolution uncertainty probable tax authority accept assistance local country tax specialists treatment tax liability recognised financial reperformed calculation estimated exposure statements reflects managements best estimate inspected thirdparty transfer pricing studies evaluated outcome based facts known relevant applicable past experience managements jurisdiction group open tax transfer pricing interactions tax authorities respective matters various tax authorities range jurisdiction additionally used tax specialists possible outcomes broad december expertise assess appropriateness key group recognised current income tax liabilities assumptions made management conclude chf million includes accruals uncertain best estimate outcome tax positions audit approach included additional audit procedures focused area uncertainty regarding performed group level consider uncertain tax positions estimates amounts tax receivable payable arising group particular respect transfer therefore require significant level expertise pricing arrangements goods services transaction judgement related tax matters information uncertain tax positions refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note income taxes roche finance report roche group statutory auditors report information annual report board directors responsible information annual report information comprises information included annual report include consolidated financial statements standalone financial statements company remuneration report auditors reports thereon opinion consolidated financial statements cover information annual report express form assurance conclusion thereon connection audit consolidated financial statements responsibility read information annual report consider whether information materially inconsistent consolidated financial statements knowledge obtained audit otherwise appears materially misstated based work performed conclude material misstatement information required report fact nothing report regard responsibility board directors consolidated financial statements board directors responsible preparation consolidated financial statements give true fair view accordance ifrs provisions swiss law internal control board directors determines necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements board directors responsible assessing groups ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate group cease operations realistic alternative auditors responsibilities audit consolidated financial statements objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law isas swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements part audit accordance swiss law isas swiss auditing standards exercise professional judgment maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease continue going concern roche finance report statutory auditors report roche group evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements represent underlying transactions events manner achieves fair presentation obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinion consolidated financial statements responsible direction supervision performance group audit remain solely responsible audit opinion communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit consolidated financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche group independent reasonable assurance report internal control financial reporting independent reasonable assurance report internal control financial reporting board directors roche holding ltd basel engaged board directors carry reasonable assurance engagement design implementation operating effectiveness system internal control financial reporting roche group place december management roche holding ltd assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso responsibilities board directors management board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting entitys internal control financial reporting process designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs entitys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate responsibilities responsibility examine design implementation effectiveness companys internal control financial reporting report thereon form independent reasonable assurance conclusion based evidence obtained conducted engagement accordance international standard assurance engagements isae assurance engagements audits reviews historical financial information issued international auditing assurance standards board standard requires plan perform procedures obtain reasonable assurance whether effective internal control financial reporting maintained material respects procedures selected depend judgement including assessment risks material misstatement design implementation effectiveness companys internal control financial reporting examination included obtaining understanding internal control financial reporting testing evaluating design implementation operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances roche finance report independent reasonable assurance report internal control financial reporting roche group independence quality control firm applies international standard quality control accordingly maintains comprehensive system quality control including documented policies procedures regarding compliance ethical requirements professional standards applicable legal regulatory requirements complied independence ethical requirements code ethics professional accountants issued international ethics standards board accountants founded fundamental principles integrity objectivity professional competence due care confidentiality professional behaviour conclusion conclusion formed basis subject matters outlined report believe evidence obtained sufficient appropriate provide basis conclusion opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group alternative performance measures financial information included financial review includes certain alternative performance measures apms accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates apms used instead considered alternatives groups consolidated financial results based ifrs apms may comparable similarly titled measures disclosed companies apms presented financial review relate performance current year comparative periods core results core results allow assessment groups actual results defined ifrs underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting impacts accounting merger acquisition transactions alliance arrangements see financial review excluded discontinued operations currently none excluded legal environmental cases see financial review excluded global issues outside healthcare sector beyond groups control excluded material treasury items major debt restructurings currently none excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary information core results reconciliation millions chf normali global intangibles alliance legal pension sation restruc amorti intangibles trans environ plan global ecp tax ifrs turing sation impairment actions mental settlements issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf normali global intangibles alliance legal pension sation restruc amorti intangibles trans environ plan global ecp tax ifrs turing sation impairment actions mental settlements issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report multiyear overview supplementary information roche group divisional core results reconciliation millions chf global intangibles alliance legal pension restruc amorti intangibles transac environ plan ifrs turing sation impairment tions mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf global intangibles alliance legal pension restruc amorti intangibles trans environ plan ifrs turing sation impairment actions mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue used calculate basic earnings per share millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf free cash flow free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business operating free cash flow calculated based ifrs operating profit adjusted certain cash items movements net working capital capital expenditures investments property plant equipment intangible assets well principal portion lease liabilities paid leased assets operating free cash flow different cash flows operating activities defined ias includes capital expenditures within responsibility divisional management excludes income taxes paid within responsibility divisional management cash outflows defined benefit plans allocated operating free cash flow based current service cost residual allocated treasury activities free cash flow calculated operating free cash flow adjusted treasury activities taxes paid free cash flow different total cash flows defined ias excludes dividend payments cash inflowsoutflows financing activities issuancerepayment debt purchasesale marketable securities cash inflowsoutflows mergers acquisitions divestments effective january group implemented ifrs leases comparative results restated main impact new standard bring operating leases onto balance sheet application new standard materially impact operating free cash flow repayment principal portion lease liabilities paid presentation almost entirely matches operating lease expenses included operating profit presentation roche finance report multiyear overview supplementary information roche group operating free cash flow free cash flow calculated shown tables additional commentary adjustment items given financial review operating free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias add back income taxes paid deduct investments property plant equipment principal portion lease liabilities paid investments intangible assets disposal property plant equipment disposal intangible assets pensions postemployment benefits add back total payments defined benefit plans deduct allocation payments operating free cash flow operating items operating free cash flow free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias deduct investments property plant equipment principal portion lease liabilities paid investments intangible assets disposal property plant equipment disposal intangible assets interest paid operating items treasury items free cash flow roche finance report roche group multiyear overview supplementary information supplementary information used calculate divisional operating free cash flow shown table divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment depreciation rightofuse assets amortisation intangible assets impairment property plant equipment impairment reversal rightofuse assets impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda group use earnings interest tax depreciation amortisation ebitda either internal management reporting external communications opinion groups management operating free cash flow gives useful consistent measurement cash earnings ebitda includes many noncash items provisions allowances trade receivables inventories certain noncash entries arising acquisition accounting pension accounting operating free cash flow also includes cash used investments property plant equipment leased assets intangible assets whereas ebitda excludes costs cash outflows items roche finance report multiyear overview supplementary information roche group convenience readers use ebitda provided table starting point uses core results already exclude amortisation impairment goodwill intangible assets ebitda information main impact implementation ifrs leases exclude depreciation impairment right ofuse assets leases group lessee previously reported operating leases effective january result groups ebitda increased approximately chf billion costs cash outflows leased assets completely excluded ebitda ebitda using core results millions chf pharmaceuticals diagnostics corporate group ebitda core operating profit depreciation impairment property plant equipment core basis depreciation impairment rightofuse assets core basis ebitda margin sales net operating assets net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment leased assets rightofuse assets goodwill intangible assets net working capital longterm net operating assets minus provisions main impact implementation ifrs leases include rightofuse assets leases group lessee previously reported operating leases part segment operating assets effective january details additional assets liabilities reported effective january provided note divisional split note calculation net operating assets disclosed note annual financial statements shown tables net operating assets reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury group property plant equipment rightofuse assets goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities lease liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets roche finance report roche group multiyear overview supplementary information net operating assets reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net assets net debt net debt used monitor groups overall short longterm liquidity net debt calculated sum total debt longterm shortterm less marketable securities cash cash equivalents net debt unaffected implementation ifrs leases groups definition net debt include lease liabilities net debt calculations including details movements current year shown table financial review net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital calculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net working capital net trade working capital calculations shown tables pharmaceuticals division diagnostics division corporate financial review constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers foreign exchange gains losses excluded calculation cer growth rates earnings per share disclosures countries significant devaluation local currency current year simulations use average exchange rate current year instead prior year avoid cer growth rates artificially inflated roche finance report roche securities roche group roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr standard poors index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january change ratio adrs effective february roche finance report roche group roche securities number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors stock codes share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies ignificant shareholders hareholders equity fulltime equivalent employees contingent liabilities board executive shareholdings appropriation available earnings statutory auditors report general meeting roche holding ltd basel roche finance report roche holding ltd basel financial statements financial statements balance sheet millions chf december december current assets cash cash equivalents marketable securities accounts receivable group companies shortterm loans group companies total current assets noncurrent assets longterm loans group companies investments total noncurrent assets total assets shortterm liabilities accounts payable group companies interestbearing liabilities group companies shortterm liabilities total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year total shareholders equity total shareholders equity liabilities pm pro memoria nonvoting equity securities genussscheine nominal value roche finance report financial statements roche holding ltd basel income statement millions chf year ended december income income investments dividend income financial income interest income loans group companies income marketable securities guarantee fee income group companies income total income expenses administration expenses expenses financial expenses direct taxes total expenses net income roche finance report roche holding ltd basel notes financial statements notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations co prescribed law significant accounting principles applied described company prepared consolidated financial statements accordance recognised accounting standard international financial reporting standards accordance co company decided forgo presenting additional information audit fees notes well cash flow statement valuation methods translation foreign currencies marketable securities reported lower cost market value financial assets including investments reported cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase equity instruments sold gain loss recognised income statement assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except investments translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred investments direct indirect investments company listed note roche group annual financial statements listing excludes chugais subsidiaries well material companies notably companies inactive dormant liquidation ownership interests equal voting rights taxes direct taxes include corporate income capital taxes shareholders equity share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates roche finance report notes financial statements roche holding ltd basel equity instruments december company hold roche shares nonvoting equity securities none company neither purchased sold roche shares nonvoting equity securities companys subsidiaries meet definitions requirements article b co hold equity instruments within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co movement recognised amounts millions chf legal voluntary reserves retained earnings retained free special available equity share capital earnings reserve reserve earnings instruments total equity january net income dividends transactions equity instruments december net income dividends transactions equity instruments december net income dividends transactions equity instruments december contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company roche finance report roche holding ltd basel notes financial statements controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares december shareholder group announced would continue shareholder pooling agreement modified shareholder composition group consists mr andr hoffmann ms marieanne hoffmann ms vera michalski mr alexander hoffmann mr frederic hoffmann ms isabel hoffmann mr lucas hoffmann ms marina hoffmann ms kasia barbotinlarrieu ms tatiana fabre mr andreas oeri ms catherine oeri ms sabine duschmal mr jrg duschmal mr lukas duschmal charitable foundation wolf artuma holding ltd shareholder pooling agreement existed since duration pool extended indefinite period figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis holding ag basel participation fulltime equivalent employees annual average number fulltime equivalent employees exceed ten people board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri certain members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine c franz hoffmann j bell j brown p bulcke h clevers na na hauser r p lifton e oeri b poussot schwan b c suessmuth dyckerhoff c c p r voser na na total include shares held shareholder group pooled voting rights b member corporate executive committee dr schwans shareholdings disclosed tables c jointly held close relative close relatives hauser held nonvoting equity securities genussscheine e r p lifton held roche american depositary receipts adrs eight adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july roche finance report notes financial statements roche holding ltd basel corporate executive committee end year members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine schwan b anderson na na heuer na na c hippe g keller b oday na na schinecker na na c wilbur total equity compensation awards ssars rsus roche performance share plan b close relatives dr keller held roche shares roche shares c december heuer held restricted stock units rsus whereof issued rsus terms vesting conditions awards disclosed note roche group annual financial statements december close relatives heuer held roche nonvoting equity securities remuneration equity compensation plans members corporate executive committee complemented restricted stock units rsus composed stocksettled stock appreciation rights ssars rsus new performance share plan psp awards granted december members corporate executive committee held stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages ssars awards granted members corporate executive committee vest four years awards granted vest three years ssars awards held december year issue total schwan b anderson hippe g keller schinecker c wilbur total strike price chf expiry date mar mar mar mar mar mar mar roche finance report roche holding ltd basel notes financial statements december members corporate executive committee held restricted stock units rsus shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages rsu awards granted members corporate executive committee vest four years awards granted vest three years thereafter nonvoting equity securities andor shares may remain blocked ten years rsu awards held december year issue total schwan b anderson hippe g keller schinecker c wilbur na na total december members corporate executive committee held performance share plan psp awards shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages award result zero two nonvoting equity securities shares value adjustment depending upon achievement performance targets discretion board directors vesting nonvoting equity securities shares may remain blocked ten years end cycle performance targets achieved accordingly participants receive originally targeted nonvoting equity securities total target number awards psp performance cycle december shown table new psp awards granted members corporate executive committee psp awards held december psp schwan b anderson hippe g keller schinecker c wilbur total allocation date feb information relating number value rights options awards granted employees roche group members board directors corporate executive committee company disclosed note note roche group annual financial statements roche finance report appropriation available earnings roche holding ltd basel appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year total appropriation available earnings carried forward account roche finance report roche holding ltd basel statutory auditors report statutory auditors report general meeting roche holding ltd basel report audit financial statements opinion audited financial statements roche holding ltd comprise balance sheet december income statement year ended notes financial statements including summary significant accounting policies opinion financial statements pages year ended december comply swiss law companys articles incorporation basis opinion conducted audit accordance swiss law swiss auditing standards responsibilities provisions standards described auditors responsibilities audit financial statements section report independent entity accordance provisions swiss law requirements swiss audit profession fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion report key audit matters based circular federal audit oversight authority key audit matters matters professional judgement significance audit financial statements current period determined key audit matters communicate report responsibility board directors financial statements board directors responsible preparation financial statements accordance provisions swiss law companys articles incorporation internal control board directors determines necessary enable preparation financial statements free material misstatement whether due fraud error preparing financial statements board directors responsible assessing entitys ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate entity cease operations realistic alternative auditors responsibilities audit financial statements objectives obtain reasonable assurance whether financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis financial statements roche finance report statutory auditors report roche holding ltd basel part audit accordance swiss law swiss auditing standards exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made c onclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt entitys ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause entity cease continue going concern communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report published cautionary statement regarding forwardlooking statements f hoffmannla roche ltd finance report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ orderdownload publications materially future reflected forwardlooking internet rochecompublications statements contained annual report among others email baselwarehouseservicesrochecom pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products media relations market fluctuations currency exchange rates general tel financial market conditions uncertainties discovery email mediarelationsrochecom development marketing new products new uses existing products including without limitation negative results clinical investor relations trials research projects unexpected side effects pipeline tel marketed products increased government pricing pressures email investorrelationsrochecom interruptions production loss inability obtain adequate protection intellectual property rights litigation corporate sustainability committee loss key executives employees adverse tel publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks legally protected links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text reporting consists actual annual report finance report contains annual financial statements consolidated financial statements regards content management report per articles incorporation consists aforementioned reports exception remuneration report printed nonchlorine bleached fsccertified papere roche finance report f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom